Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC
Phase: PHASE3
Conditions: Clear Cell Renal Carcinoma
Sponsor: SFJ Pharma Ltd. II

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 1 
CLINICAL PROTOCOL 
ADJUVANT AXITINIB TREATMENT OF RENAL CANCER: A RANDOMIZED 
DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT AXITINIB VS. PLACEBO IN 
SUBJECTS AT HIGH RISK OF RECURRENT RCC 
Compound: 
AG-013736 
Compound Name (if applicable): 
Axitinib 
Protocol Number: 
AP311736 
 
Phase: 
3 
Version and Date 
 
version - #10 March 21, 2017 
Good Clinical Practice Statement: 
 
 
 
 
 
 
This study is to be performed in full compliance with 
all International Conference on Harmonization (ICH) 
and all applicable local Good Clinical Practices 
(GCP) and regulations. All required study 
documentation will be archived per regulatory 
authorities’ requirements. 
 
This document contains confidential information belonging to Sponsor.  Except as otherwise 
agreed to in writing, by accepting or reviewing this document, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it 
for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, 
Sponsor must be promptly notified. 

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 2 
SUMMARY 
Indication: 
Adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following 
nephrectomy. 
Background: 
Kidney cancer is diagnosed in approximately 270,000 people each year worldwide, and 
results in 120,000 deaths. RCC is the most common form of kidney cancer. Up to 30% of 
patients treated by nephrectomy for localized disease will relapse.  Hormonal, 
chemotherapeutic, and radiation therapy approaches have failed to significantly improve 
clinical outcomes, particularly for patients with metastatic disease. 
Approximately 45% of RCC patients present with “localized” disease (tumor, nodes, 
metastatis [TNM] Stage I/II) at the time of diagnosis, 25% “locally advanced” disease (Stage 
III) and 30% “metastatic” disease (TNM Stage IV).  Additionally, approximately 30% of 
patients with “localized” and “locally advanced” disease at the time of diagnosis will develop 
metastatic disease later on.  TNM Stage II, III and IV RCC patients have 5-year survival rates 
of 65-80%, 40-60% and 0-20%, respectively.  
Axitinib is an oral, potent and selective inhibitor of vascular endothelial growth factor 
(VEGF) receptors 1, 2, and 3. The safety and efficacy of axitinib is being evaluated in 
patients with a variety of solid tumors. 
VEGF receptors are critical components of the processes leading to the branching, extension, 
and survival of endothelial cells which form new blood vessels during angiogenesis, an 
absolute necessity for tumor growth beyond microscopic size. In nonclinical tumor mouse 
models, twice daily (BID) oral administration of axitinib demonstrated consistent and 
significant anti-tumor efficacy (marked inhibitory effect on local and distant tumor 
metastasis and prolonged animal survival). 
A Phase 2 study of single-agent axitinib in patients with cytokine-refractory metastatic RCC 
(mRCC) showed an objective response rate (ORR) of 44.2%, with 21 partial responders 
(PRs) and 2 complete responders (CRs) out of 52 patients.  The median time to progression 
(TTP) was 15.7 months and median overall survival (OS) was 29.9 months.  Another Phase 2 
study of single-agent axitinib in Japanese patients with cytokine-refractory mRCC 
demonstrated ORR of 50.0%, with 32 PRs out of 64 patients.  The median progression-free 
survival (PFS) was 11.0 months.  Both data were based on the assessment by an Independent 
Review Committee (IRC).  A third Phase 2 study of single-agent axitinib in patients with 
sorafenib-refractory mRCC showed ORR of 23% and a median PFS of 7.4 months (N=62).  
In a subset of 14 patients previously treated with both sorafenib and sunitinib, one patient 
achieved a PR and the median PFS was 7.1 months.  These results suggest that axitinib may 
provide clinical benefit to patients with mRCC following failure of prior systemic first-line 
therapy.   
In a Phase 3 study, efficacy and safety of axitinib versus (vs) sorafenib were confirmed in 
patients with advanced RCC following failure of one prior systemic first-line therapy.  

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 3 
Axitinib demonstrated a significantly longer PFS and higher ORR vs sorafenib with an 
acceptable safety profile as second-line therapy for mRCC.  Axitinib was approved by US 
Food and Drug Administration (FDA) in January 2012 with an indication for the treatment of 
advanced RCC after failure of one prior systemic therapy.  Axitinib was also approved in 
Japan, Korea and other countries in 2012 for the same indication. 
Objectives:  
Primary Objective: 
• To demonstrate an improvement in disease free survival (DFS) in patients at high risk 
of recurrent RCC randomly assigned to adjuvant axitinib (Arm A) vs. Placebo (Arm 
B) after nephrectomy. 
Secondary Objectives:  
• Compare OS associated with Arm A to that associated with Arm B 
• Assess safety/toxicity profile of administration of axitinib 
Trial Design: 
This is a prospective, randomized, double-blind placebo controlled Phase 3 trial of oral 
axitinib starting at 5 mg twice daily vs. placebo given for up to 3 years, with a minimum of 1 
year. The dose may be increased or decreased depending on individual patient tolerance of 
axitinib.   
A total of approximately 700 patients will be randomized in a 1:1 ratio between axitinib vs 
placebo.  Patients should begin study treatment within 7 days after randomization.  
Randomization will occur no sooner than 4 weeks post-nephrectomy and no later than 12 
weeks post-nephrectomy. 
Recurrence or occurrence of a secondary malignancy will be followed up, by clinic visit 
(See Section 6.4 for further details), until the time of the final analysis (regardless of the 
duration of treatment) every 16 weeks for the first 3 years from initiation of study treatment 
(also, at the end of treatment) and every 6 months thereafter for the remainder of the follow-
up period. 
All patients will be followed up for OS status (regardless of the duration of treatment) every 
16 weeks until the time for final DFS analysis.  Survival status can be ascertained by 
telephone contact.  At the time of final DFS analysis, OS results will be analyzed and 
summarized. 
Study Scheme: 
 
 
 
 
 
Arm A: axitinib 
Arm B: placebo 
Randomization 
Follow-up 
Treatment: Up to 3 years, with 
a minimum of 1 year 

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 4 
Endpoints: 
Primary Endpoint: 
• DFS is defined as the time interval from the date of randomization to the first date of 
recurrence (distant or local recurrence of RCC) or the occurrence of a secondary 
malignancy or death.  The primary DFS analysis will be based on assessments by the 
Independent Review Committee (IRC).  IRC will review all imaging data.  
Additionally, in cases for which there is site confirmation of recurrence or occurrence 
of a secondary malignancy in the absence of IRC imaging confirmation, available 
local histo-/cytopathology reports will also be reviewed by the IRC oncologist to 
determine confirmation of recurrence or occurrence of a secondary malignancy. 
• Recurrence refers to relapse of the primary tumor in situ or at metastatic sites.  The 
date of recurrence or the occurrence of a secondary malignancy is defined as the date 
of the tumor scan or the date of collection of the histo-/cytopathological specimen 
(for patients who have site confirmation of recurrence or occurrence of secondary 
malignancy in the absence of IRC imaging confirmation) that demonstrated 
unequivocal recurrence or a secondary malignancy according to protocol criteria.    If 
both imaging and histo-/cytopathological confirmation of recurrence or secondary 
malignancy are available, the earlier of the two dates will be considered. 
• For patients with no DFS event, DFS time will be censored at the date of the last scan 
prior to the time of the analyses.  Patients alive who do not have post-baseline disease 
assessments will have their DFS times censored at randomization.  For patients 
receiving further anti-tumor therapy prior to recurrence or occurrence of a secondary 
malignancy or death, DFS will be censored on the date of the last scan prior to taking 
the anti-tumor medication.  Patients who miss 2 or more consecutive tumor scans 
immediately followed by an event will be censored at the date of the last objective 
tumor assessment prior to the missing/not readable scans. 
Secondary Endpoints: 
• OS, defined as the time from the date of randomization to the date of death due to any 
cause.  In the absence of confirmation of death, survival time will be censored at the 
last date the patient is known to be alive.  Patients lacking data beyond randomization 
will have their survival times censored at randomization. 
• Type, incidence, severity (graded by the National Cancer Institute [NCI] Common 
Terminology Criteria for Adverse Events [CTCAE] Version 4.0), timing, seriousness, 
and relatedness of adverse events, and laboratory abnormalities. 
Trial Treatments: 
Patients will receive a starting dose of 5 mg of axitinib or placebo twice daily (BID) taken 
orally with or without food.  Study drug will be taken beginning on Day 1 of the study.  
Doses should be taken approximately 12 hours apart.  Patients should be instructed to take 
their doses at approximately the same times each day.  If a patient vomits or misses a dose, 
an additional dose should not be taken. The next prescribed dose should be taken at the usual 

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 5 
time.  Missed or vomited doses must be indicated in the source documents and Case Report 
Forms (CRFs).  Study drug will be administered in cycles of 4 weeks in duration. 
Patients who tolerate axitinib or placebo with no adverse events related to study drug above 
CTCAE Grade 2 for a consecutive 2 week period may have their dose increased by one dose 
level to a maximum of 10 mg BID (unless the patient’s blood pressure is >150/90 mm Hg or 
the patient is receiving antihypertensive medication).  The clinical judgment of the treating 
investigator should be exercised in titrating axitinib dose. 
Patients experiencing drug reaction should undergo dose modification as recommended in 
Section 5.3.4. 
Available Axitinib/Placebo Dose Levels: 
Dose Level 
Dose 
Dispensed As 
+2 
10 mg BID 
2 X 5 mg Tablets BID  
+1 
7 mg BID 
1 X 5 mg Tablet  BID + 2 X 1mg Tablets BID 
0 (Starting Dose) 
5 mg BID 
1 X 5 mg Tablet BID (twice daily) 
-1 
3 mg BID 
3 X 1 mg Tablets BID     
-2 
2 mg BID 
2 X 1 mg Tablets BID     
-3 
1 mg BID 
1 X 1 mg Tablet BID     
 
Statistical Methods: 
Two analysis populations will be defined: 
1. Intent-to-Treat Population: This population will include all patients who are 
randomized, with study drug assignment designated according to initial 
randomization, regardless of whether patients receive study drug or receive a different 
drug from that to which they were randomized.  This will be the primary population 
for evaluating all efficacy endpoints as well as patient characteristics;  
2. As-Treated Population: The as-treated population consists of all patients who 
received at least 1 dose of study drug with treatment assignments designated 
according to actual study drug received.  This population will be the primary 
population for evaluating study drug administration/compliance and safety.  
Sample Size Calculation:  
The patient population in this study can be classified into 4 risk groups based on American 
Joint Committee on Cancer (AJCC) TNM staging version 2010, Eastern Collaborative 
Oncology Group (ECOG) performance status (PS). Any Fuhrman grades are eligible. The 
patient risk groups will be as follows. Group a will be closed for further enrollment, to keep 
the number of patients of groups b, c, and d with about 90% or more: 
a. 
pT2, pN0 or pNx, M0 and ECOG PS 0-1 
b. pT3, pN0 or pNx, M0 and ECOG PS 0-1 
c. 
pT4, pN0 or pNx, M0 and ECOG PS 0-1 

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 6 
d. Any pT, pN1, M0 and ECOG PS 0-1 
Sample size was determined based on the analysis on the primary endpoint, DFS. 
The sample size for this study was calculated based on the following assumptions: 
• Time to DFS event follows an exponential distribution.  
• The percentage of patients randomized from the 4 risk groups, 2-year DFS rates for 
placebo arm and axitinib arm are assumed below: 
Categories 
Risk groups 
Percentage of 
patients 
2-year DFS rate for 
placebo arm 
2-year DFS rate for 
axitinib arm 
1 
a. pT2/pN0 or pNX/M0 
b. pT3/pN0 or pNX/M0 
90% 
70% 
79% 
2 
c. pT4/pN0 or pNX/M0 
1% 
35% 
61% 
3 
d. Any pT/pN1/M0 
9% 
33% 
51% 
 
The assumptions of 2-year DFS rates for the placebo arm and axitinib arm are equivalent to 
the assumptions of hazard ratios to be 0.66, 0.47, and 0.61 for the 3 categories 1, 2 and 3 
respectively.  Given the assumed distribution of patients randomized (1:1) into each of these 
categories, the overall hazard ratio is estimated to be 0.654. 
Based on the above assumptions, a minimal number of 245 DFS events will be required to 
provide 90% power to detect the statistical difference in DFS with HR ≤ 0.654 between the 
two treatment groups with 2-sided significance level of 0.05. 
Applying a 1:1 randomization and a planned accrual period of 24 months, a maximum study 
period of 60 months (5 years), and an assumed 23% drop-out rate by 18 months, it was 
estimated that approximately 700 patients will be enrolled.   
The final analysis will take place when approximately 245 DFS events are observed. 
Interim Analysis: 
A single interim analysis (IA) of efficacy and safety will be performed after approximately 
184 DFS events (approximately 75% of the total number of required events as assessed by 
the IRC) have occurred.  If the event occurrence pace is much slower than anticipated, the IA 
could be performed when less than 184 events observed (<75% of the total required) at 
sponsor’s discretion with the Data Monitoring Committee’s (DMC) consensus.  To protect 
the integrity of the study and to preserve the Type 1 error, a fraction of alpha will be spent at 
the interim analysis based on an O’Brien-Fleming stopping boundary.  
The objectives of the interim analysis will be: 
• To assess the safety, including any unexpected toxicity. 
• To allow for early stopping of the trial due to futility. 
• To assess the efficacy of the study drug to allow stopping of trial for success of 
efficacy. 

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 7 
Schedule of Assessments 
Screening 
Treatment with axitinib or placebo1 
Post-Treatment 
Protocol Activities and 
Forms to be Completed 
(See Protocol 
Section 6.1) 
Cycle 1 
(1 cycle = 4 weeks) 
Subsequent 
Cycles2 
EOT or 
Withdrawal3 
28 Days Post-  
Treatment 
DFS 
Follow-up 
Survival 
Follow-Up 
Day 1 
  
Day 15 
(-7/+2 days) 
Day 1 
 (-7/+2 days) 
 
(0/+7 days) 
 (-7/+7 days) 
 
Informed Consent4 
X 
 
 
 
 
 
 
 
Medical History, illnesses and 
demographics 
X 
 
 
 
 
 
 
 
Physical Examination 
X* 
X 
X5 
X 
X 
 
 
 
Vital signs6, body weight 
X* 
X 
X5 
X 
X 
 
 
 
Home Blood Pressure Monitoring7 
 
Throughout the study period 
 
 
 
 
Height 
X* 
 
 
 
 
 
 
 
Hematology8 
X* 
 
 
X 
X 
 
 
 
Blood Chemistry8 
X* 
 
 
X 
X 
 
 
 
Urinalysis8 
X* 
 
 
X 
X 
 
 
 
Thyroid Function Tests9 
 
X 
X5 
X 
X 
 
 
 
Pregnancy Test if applicable10 
X* 
 
 
 
 
 
 
 
12-lead electrocardiogram11 
X* 
 
 
 
 
 
 
 
ECOG Performance Status12 
X 
X 
 
X 
X 
 
 
 
CT or MRI of brain13 
X 
 
 
 
 
 
 
 
Tumor Imaging14 
X 
 
 
X 
Every 16 weeks 
X 
 
X 
 
Histo-/cytopathology15 
X 
X 
Study Randomization16 
X (Day -7 to 1) 
 
 
 
 
 
 
 
Study Treatment17 
 
X 
 
X 
 
 
 
 
Adverse Events18 
X 
X 
X5 
X 
X 
X 
 
 
Study Drug Compliance19 
 
 
 
X 
X 
 
 
 
Prior/Concomitant Medications 
and Treatments20 
X 
X 
X5 
X 
X 
X 
 
 
Follow-up Survival Status21 
 
 
 
 
 
 
 
X 
*: Should be assessed within 14 days of randomization. 
 
 
 
 
 
 
 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 8 
Footnotes for Schedule of Assessments  
1. 
During Treatment:  Acceptable time windows for performing each assessment are described in the column headings.   
2. 
Subsequent Cycles: Assessments other than tumor imaging should be done at Day 1 of every cycle (4 weeks) until Cycle 5 Day1, then every 8 weeks thereafter starting from 
Cycle 7 Day 1. 
3. 
End of Treatment (EOT)/Withdrawal: At the end of the study or at withdrawal, these assessments should be performed if they were not performed within 7 days of the end 
of the study or at withdrawal. Tumor imaging should be obtained if they were not performed within 8 weeks of the end of the study or at withdrawal for patients who 
discontinue treatment for reasons other than disease progression. 
4. 
Informed Consent: Must be obtained before undergoing any study specific procedure and may occur prior to the screening period. 
5. 
Cycle 1 Day 15: Assessments should be performed via telephone contact or visit.  In case of telephone contact, only adverse events assessment should be performed. 
6. 
Vital signs: Temperature, blood pressure and pulse rate will be measured.  Blood pressure should be measured with the patient in the seated position after the patient has been 
sitting quietly for 5 minutes. 
7. 
Home Blood Pressure Monitoring: All patients will be provided a blood pressure monitoring device.  Patients should measure their blood pressure prior to taking each dose 
of study drug (twice daily) for the first 3 months, and once a week thereafter.  Following dose modification of study drug or anti-hypertensive medication, or changes of anti-
hypertensive medication, patients should restart blood pressure measurements prior to taking each dose of study drug for the first 3 months and once a week thereafter.  
Patients should record all blood pressure measurements in their patient diary.  Patients should be instructed by the study staff to contact their investigator immediately for 
guidance if their systolic blood pressure rises above 150 mm Hg, diastolic blood pressure rises above 100 mm Hg, or if they develop symptoms perceived to be related to 
elevated blood pressure (eg, headache, visual disturbance). 
8. 
Hematology, Blood Chemistry, Urinalysis: See Appendix 1 of the protocol for required tests.  Hematology, chemistry and urinalysis will be done 2 weeks prior to starting 
treatment (screening).  Results of the tests must be awaited before randomizing patients.  Thus, days for test results should be taken into consideration.  After the first cycle, 
the hematology, chemistry and urinalysis will be repeated at Day 1 of every cycle (4 weeks) until Cycle 5 Day1, then every 8 weeks thereafter starting from Cycle 7 Day 1.  If 
urine protein is ≥2+ by semi-quantitative method (ie, dipstick) at screening or on study, then urine protein:urine creatinine ratio should be performed.  PT/INR should be 
performed to monitor patients receiving concomitant warfarin or other anti-coagulants and when clinically indicated. 
9. 
Thyroid Function Tests: Thyroid Function Tests (TSH, free T3 and free T4) should be performed for all patients at baseline (Cycle 1 Day 1 pre-dose).  Subsequently, TSH 
should be done at Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, then every 8 weeks thereafter starting from Cycle 7 Day 1.  TSH, Free T3 
and free T4 should be performed on the next visit for any patient who has elevated TSH.  Hypothyroidism should be treated per standard medical practice to maintain 
euthyroid state with a normal TSH. 
10. Pregnancy Testing: Patient of childbearing potential must have a negative pregnancy test within 14 days prior to the date of randomization and must be using appropriate 
birth control or practicing abstinence. Pregnancy tests may also be repeated as per request of IRB/IECs or if required by local regulations. 
11. 12-lead electrocardiogram (ECG):  To determine the QTc interval at screening, the average of three consecutive 12-lead ECGs should be done.  Screening ECG should be 
performed no more than 2 weeks prior to randomization. If the QTc interval is prolonged (>500 msec), the ECG should be re-read by a cardiologist at the site for 
confirmation.  ECGs should be repeated as clinically indicated. 
12. ECOG Performance Status (ECOG PS): Evaluation of ECOG PS at screening should reflect the patient condition just prior to nephrectomy.  Baseline ECOG PS should be 
made prior to randomization and start of treatment. Follow-up assessments will be done at Day 1 of every cycle (4 weeks) until Cycle 5 Day1, then every 8 weeks thereafter 
starting from Cycle 7 Day 1. 
13. CT or MRI of brain: To be done at screening and the images sent to the IRC for retrospective confirmation.  Patients with any evidence of brain metastasis must be 
excluded from the study.  Images should be submitted for IRC review before Week 8 post-nephrectomy to allow for return of the results before Week 12 and in the event a 
repeat scan is needed.  Brain CT or MRI within 12 weeks prior to randomization is acceptable regardless of whether it is before or after nephrectomy.  Subsequent CT or MRI 
of brain is not required, but may be performed if clinically indicated. 
14. Tumor Imaging: Pre-surgery images are requested, if available, and should be submitted for IRC review. Screening visit imaging will be reviewed by IRC, designated by the 
sponsor, and must be performed at least 3 weeks after nephrectomy.  Images should be submitted for IRC review before Week 8 post-nephrectomy to allow for return of the 
results before Week 12 and in the event a repeat scan is needed.  CT or MRI of the chest, abdomen and pelvis for DFS should be performed (regardless of the duration of 
treatment) every 16 weeks for the first 3 years from initiation of study treatment (also, at the end of treatment).  Allowable window for assessment is +/- 7 days.  Thereafter, 

AP311736 
Version - #10 Mar. 21, 2017 
 
 CONFIDENTIAL 
Page 9 
Footnotes for Schedule of Assessments  
imaging should be repeated every 6 months for the duration of the DFS follow-up period.  Additional imaging of potential disease sites should be performed whenever 
recurrence or occurrence of a secondary malignancy is suspected.  Bone scan (confirmatory imaging in addition to bone scan may be required), if clinically indicated. 
15. Histo-/cytopathology: Local histopathology confirmation of eligibility is required.  After randomization, in cases for which there is site confirmation of recurrence or 
occurrence of a secondary malignancy in the absence of IRC imaging confirmation, available local histo-/cytopathology reports should be submitted to the IRC for review. 
16. Study Randomization: Patients must be randomized by 12 weeks after nephrectomy.  Patient eligibility must be confirmed by IRC review for imaging and by a sponsor 
designated laboratory.  Patients must be randomized based on the assessment by the IRC when there is a discrepancy between the local and the IRC imaging review.  
17. Study Treatment: Should be started within 7 days after randomization.  It is not necessary to repeat the Day 1 procedures if treatment is not started on the same day as 
randomization.  Patients will receive either axitinib tablets at a starting dose of 5 mg BID or placebo according to randomization.  The axitinib/placebo dose may be adjusted 
up or down according to individual patient tolerance per protocol dose modification procedure.   Study drug are dispensed on Day 1 of each cycle. 
18. Adverse Events (AEs): Will be collected from the first day of study treatment until at least 28 days after the last on-study drug administration (Allowable window for 
assessment is 0/+7 days.), or until all serious or study drug-related toxicities have resolved or are determined to be “chronic” or “stable,” whichever is later.  Serious adverse 
events should be monitored and reported from the time that the patient provides informed consent and as described in the protocol.  
19. Study Drug Compliance: The study drug bottle(s) including any unused tablets will be returned to the clinic for drug accountability.   
20. Prior/Concomitant Medications and Treatments: Will be recorded from the time the patient has signed informed consent until 28 days after last treatment.  Allowable 
window for assessment is 0/+7 days.  Anti-tumor therapy should be recorded even after 28 days after last treatment. 
21. Follow-up Survival Status: Survival status information should be collected, approximately every 16 weeks (+/- 2 weeks) from DFS events, until the time for final DFS 
analysis.  Survival information can be done via telephone contact.   
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 10 
TABLE OF CONTENTS 
TABLE OF CONTENTS ................................................................................................................................... 10 
LIST OF TABLES .............................................................................................................................................. 12 
LIST OF FIGURES ............................................................................................................................................ 13 
LIST OF APPENDICES .................................................................................................................................... 13 
1. INTRODUCTION .......................................................................................................................................... 14 
1.1. Background ............................................................................................................................................... 14 
1.1.1. Renal Cell Carcinoma Epidemiology and Treatment ........................................................................ 14 
1.1.2. Molecular Formula ............................................................................................................................ 15 
1.1.3. Phase 2 Clinical Trials of Single-Agent Axitinib in mRCC.............................................................. 15 
1.1.3.1. Cytokine-Refractory mRCC Studies ......................................................................................... 15 
1.1.3.2. Sorafenib- and Sunitinib-Failure mRCC Study ......................................................................... 16 
1.1.4. Comparative Effectiveness Phase III Study of Axitinib in second line mRCC ................................ 16 
1.2. Rationale ................................................................................................................................................... 19 
2. TRIAL OBJECTIVES ................................................................................................................................... 19 
2.1. Primary Objective ..................................................................................................................................... 19 
2.2. Secondary Objectives ............................................................................................................................... 20 
3. TRIAL DESIGN ............................................................................................................................................. 20 
4. SUBJECT SELECTION ................................................................................................................................ 20 
4.1. Inclusion Criteria ...................................................................................................................................... 21 
4.2. Exclusion Criteria ..................................................................................................................................... 22 
4.3. Randomization Criteria ............................................................................................................................. 24 
4.4. Life Style Guidelines ................................................................................................................................ 25 
5. TRIAL TREATMENTS ................................................................................................................................ 25 
5.1. Allocation to Treatment ............................................................................................................................ 25 
5.2. Breaking the Blind .................................................................................................................................... 25 
5.3. Drug Supplies ........................................................................................................................................... 25 
5.3.1. Formulation and Packaging............................................................................................................... 26 
5.3.2. Preparation and Dispensing............................................................................................................... 26 
5.3.3. Administration .................................................................................................................................. 26 
5.3.4. Dose Interruption and Reduction ...................................................................................................... 27 
5.3.4.1. Management of Axitinib/Placebo-Related Adverse Events ...................................................... 27 
5.3.4.2. Axitinib/Placebo Dose Reduction for Hypertension ................................................................. 28 
5.3.4.3. Axitinib/Placebo Dose Reduction for Proteinuria ..................................................................... 29 
5.3.4.4. Axitinib/Placebo Dose Interruption for Surgery or Surgical Procedures .................................. 30 
5.3.5. Compliance ....................................................................................................................................... 30 
5.4. Drug Storage and Drug Accountability .................................................................................................... 30 
5.5. Prior/Concomitant Therapy ...................................................................................................................... 31 
5.5.1. Prior/Concomitant Medication .......................................................................................................... 31 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 11 
5.5.2. Concomitant Radiotherapy................................................................................................................ 32 
6. TRIAL PROCEDURES ................................................................................................................................. 32 
6.1. Screening .................................................................................................................................................. 32 
6.1.1. Screening Procedures between Nephrectomy and Starting Treatment ............................................. 33 
6.1.2. Screening Procedures Within 2 Weeks Prior to Randomization ....................................................... 33 
6.2. Trial Period ............................................................................................................................................... 34 
6.2.1. Treatment Procedures First Cycle ..................................................................................................... 34 
6.2.1.1. Day 1 ......................................................................................................................................... 34 
6.2.1.2. Day 15 ....................................................................................................................................... 35 
6.2.2. Treatment Procedures Subsequent Cycles ........................................................................................ 35 
6.2.3. End of Study Treatment/Withdrawal from treatment Procedures ..................................................... 36 
6.3. 28 Days Post Treatment Follow-Up Visit ................................................................................................. 37 
6.4. Recurrence or occurrence of secondary malignancy and Survival Follow-Up ......................................... 37 
6.5. Patient Withdrawal ................................................................................................................................... 38 
6.5.1. Withdrawal from treatment ............................................................................................................... 38 
6.5.2. Withdrawal from trial........................................................................................................................ 38 
7. ASSESSMENTS ............................................................................................................................................. 39 
7.1. Efficacy Assessments ............................................................................................................................... 39 
7.1.1. Primary Endpoint .............................................................................................................................. 40 
7.1.2. Secondary Endpoints......................................................................................................................... 41 
7.2. Safety Assessments ................................................................................................................................... 41 
7.2.1. Adverse Events ................................................................................................................................. 41 
7.2.2. Laboratory Safety Assessments ........................................................................................................ 41 
7.2.3. Other Safety Assessments ................................................................................................................. 42 
8. Adverse Event Reporting ............................................................................................................................... 42 
8.1. Adverse Events ......................................................................................................................................... 42 
8.2. Reporting Period ....................................................................................................................................... 43 
8.3. Definition of an Adverse Event ................................................................................................................ 43 
8.4. Abnormal Test Findings ........................................................................................................................... 44 
8.5. Serious Adverse Events ............................................................................................................................ 44 
8.6. Hospitalization .......................................................................................................................................... 45 
8.7. Severity Assessment ................................................................................................................................. 46 
8.8. Causality Assessment ............................................................................................................................... 47 
8.9. Exposure In Utero ..................................................................................................................................... 47 
8.10. Withdrawal Due to Adverse Events (See Also Patient Withdrawal) ...................................................... 48 
8.11. Eliciting Adverse Event Information ...................................................................................................... 48 
8.12. Reporting Requirements ......................................................................................................................... 48 
8.12.1. Serious Adverse Event Reporting Requirements ............................................................................ 49 
8.12.2. Non-Serious Adverse Event Reporting Requirements .................................................................... 49 
9. DATA ANALYSIS/STATISTICAL METHODS ........................................................................................ 49 
9.1. Sample Size Determination ...................................................................................................................... 50 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 12 
9.2. Efficacy Analysis ...................................................................................................................................... 51 
9.2.1. Analysis of Primary Endpoint ........................................................................................................... 51 
9.2.2. Analysis of Secondary Endpoints ..................................................................................................... 52 
9.3. Analysis of Other Endpoints ..................................................................................................................... 52 
9.3.1. Patient Disposition ............................................................................................................................ 52 
9.3.2. Baseline Characteristics .................................................................................................................... 52 
9.3.3. Study drug Administration/Compliance............................................................................................ 52 
9.4. Safety Analysis ......................................................................................................................................... 52 
9.4.1. Analysis of Adverse Events .............................................................................................................. 52 
9.4.2. Analysis of Clinical Laboratory Data................................................................................................ 53 
9.4.3. Prior/Concomitant Medications and Non Drug Treatments/Procedures ........................................... 53 
9.4.4. Vital Sign and ECOG PS .................................................................................................................. 53 
9.5. Interim Analysis........................................................................................................................................ 53 
9.6. Data Monitoring Committee ..................................................................................................................... 54 
9.7. Independent Review Committee (IRC) .................................................................................................... 55 
10. QUALITY CONTROL AND QUALITY ASSURANCE .......................................................................... 55 
11. DATA HANDLING AND RECORD KEEPING ....................................................................................... 55 
11.1. Case Report Forms/Electronic Data Record ........................................................................................... 55 
11.2. Record Retention .................................................................................................................................... 56 
12. ETHICS ......................................................................................................................................................... 56 
12.1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) ............................................... 56 
12.2. Ethical Conduct of the Trial .................................................................................................................... 56 
12.3. Patient Information and Consent ............................................................................................................ 56 
13. DEFINITION OF END OF TRIAL ............................................................................................................ 57 
14. SPONSOR DISCONTINUATION CRITERIA ......................................................................................... 57 
15. PUBLICATION OF TRIAL RESULTS ..................................................................................................... 57 
16. REFERENCES ............................................................................................................................................. 58 
 
LIST OF TABLES 
Table 1 
Adverse Reaction (Phase III study) ............................................................................18 
Table 2 
Available Axitinib/Placebo Dose Levels ....................................................................27 
Table 3 
Criteria for Dose Modification for Axitinib/Placebo – Related Adverse 
Events Other Than Hypertension Or Proteinuria ........................................................27 
Table 4 
 Hypertension Management Plan for Axitinib/Placebo ..............................................29 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 13 
LIST OF FIGURES 
Figure 1 Molecular Formula .......................................................................................................15 
Figure 2 Kaplan-Meier Curve for Progression- Free Survival by Independent 
Assessment for the Overall Population .......................................................................17 
Figure 3 Screening Procedures ...................................................................................................33 
 
LIST OF APPENDICES 
Appendix 1. Required Laboratory Tests ........................................................................................62 
Appendix 2. ECOG Performance Status ........................................................................................63 
Appendix 3. National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) ..........................................................................................64 
Appendix 4. Nephrectomy Procedure. ...........................................................................................65 
Appendix 5. Abbreviations and Definitions of Terms ...................................................................66 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 14 
1. INTRODUCTION 
1.1. Background 
1.1.1. Renal Cell Carcinoma Epidemiology and Treatment 
Kidney cancer is diagnosed in approximately 270,000 people each year worldwide, and 
results in 120,000 deaths. Renal cell carcinoma (RCC) is the most common form of kidney 
cancer.1  Up to 30% of patients treated by nephrectomy for localized disease will relapse.2  
Hormonal, chemotherapeutic, and radiation therapy approaches have failed to significantly 
improve clinical outcomes, particularly for patients with metastatic disease. 
Clear cell RCC, which represents 75% to 85% of the RCC population, frequently displays 
allelic loss on chromosome 3p, accompanied by mutational inactivation of the Von 
Hippel-Lindau (VHL) tumor suppressor gene.3, 4  VHL-associated RCC are known for their 
vascularity and these tumors produce high levels of vascular endothelial growth factor 
(VEGF). 5, 6, 7  In addition, recent studies suggest that in sporadic clear cell RCC, increased 
expression of VEGF is closely correlated with neovascularization, which is a prerequisite of 
tumor growth and metastasis.8  RCC tumors overexpress the receptors for these peptides.  
These ligands and receptors may be involved in the autocrine stimulation of tumor cell 
growth, or in the paracrine stimulation of neovascular or stromal fibroblast growth that 
supports tumor expansion. 
Approximately 45% of RCC patients present with “localized” disease (tumor, nodes, 
metastatis [TNM] Stage I/II) at the time of diagnosis, 25% “locally advanced” disease (Stage 
III) and 30% “metastatic” disease (TNM Stage IV).  Additionally, approximately 30% of 
patients with “localized” and “locally advanced” disease at the time of diagnosis will develop 
metastatic disease later on.  TNM Stage II, III and IV RCC patients have 5 year survival rates 
of 65-80%, 40-60% and 0-20%, respectively.  
Hormonal, chemotherapeutic, and radiation therapy approaches have failed to significantly 
improve clinical outcomes for patients with metastatic RCC (mRCC).  Recently-published 
trials included reports on thalidomide, 5-FU, and cis-retinoic acid, none of which showed 
clear benefit.  Studies of chemotherapy combined with cytokine therapy have also been 
discouraging.  Notwithstanding, cytokine therapies have been commonly used in the 
treatment of mRCC albeit with limited anti-tumor response.  Interferon-α (IFN-α) has an 
approximately 15% objective response rate (ORR) in appropriately selected individuals.10  In 
general, these patients have non-bulky pulmonary and/or soft tissue metastases with excellent 
PS (Eastern Collaborative Oncology Group (ECOG) performance status (PS) 0 or 1) without 
weight loss.  These responses are rarely complete or durable, but the result of a study 
suggests that IFN-α improves survival.11  Administration of high-dose interleukin-2 (IL-2) 
appears to have a similar overall response rate to IFN-α, but with approximately 5% of the 
appropriately selected patients having durable complete remissions.  Combinations of IL-2 
and IFN-α have been studied, but have not shown an overall survival (OS) advantage over 
monotherapy.  The optimum dose of IL-2 is unknown.  High-dose therapy has been approved 
in the United States, and while it appears to be associated with higher response rates, the 
incidence of toxic effects is also high.12, 13, 14, 15  Low-dose IL-2 regimens produce lower 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 15 
response rates but can be administered with fewer toxic effects, especially hypotension.16  
Attempts to improve relapse-free survival and OS using cytokine or immune-based 
treatments were equally discouraging providing no evidence for improved relapse-free or 
OS.17, 18, 19 
Several anti-angiogenic agents have shown activity in the treatment of mRCC.  In the 
first-line treatment of mRCC, sunitinib has demonstrated dramatically improved median 
progression free survival (PFS) over IFN (11 months vs 5 months; hazard ratio 0.42; p < 
0.001)20 and is now considered to be the standard of care for the first-line treatment of 
patients with mRCC.  In similar first-line setting, the final analysis of a randomized Phase 3 
(AVOREN) trial of bevacizumab in combination with IFN versus IFN alone demonstrated 
that bevacizumab significantly improved PFS and showed a trend toward improvement in OS 
in patients with mRCC. 21, 22  In second-line setting after cytokine failure, sorafenib has 
demonstrated superior PFS over placebo with the median PFS of 5.5 months.23    
1.1.2. Molecular Formula  
Axitinib, a substituted indazole derivative, is an oral, potent, and selective inhibitor of VEGF 
receptors 1, 2, 3.  The molecular formula is C22H18N4OS with molecular weight of 386.47.  
The chemical name is 
N-Methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide:  
Figure 1 Molecular Formula 
H
N
N
S
C O N H Me
N
 
 
1.1.3. Phase 2 Clinical Trials of Single-Agent Axitinib in mRCC 
Three Phase 2 studies have been conducted to explore the safety and efficacy of axitinib in 
mRCC patients. 
1.1.3.1. Cytokine-Refractory mRCC Studies 
The Phase 2 study (Protocol A4061012) enrolled 52 patients with mRCC who were 
refractory to cytokine treatment.  Two complete responses (CRs) and 21 partial responders 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 16 
(PRs) were observed, for an ORR of 44.2%.  The median time to progression (TTP) was 15.7 
months and the median OS was 29.9 months. 24 
Long-term survival data were collected via an observational study (Protocol A4061065). 25 
Of the 52 patients, 35 died of progressive disease, 5 died of “unknown causes,” 10 were 
alive, and 2 were lost to follow-up. Median follow-up for OS was 5.9 yrs. The 5-year 
survival rate was 20.6% (95% confidence interval [CI], 10.9–32.4%). Treatment-emergent, 
all-causality grade ≥3 adverse events for the 52 patients included diarrhea (19%), fatigue 
(19%), hypertension (17%), weight loss (8%), and dehydration, myocardial infarction, and 
stomatitis (6% each). Hypothyroidism (all grades) was observed in 23%. Comparing the 
characteristics of the 5-year survivors (n = 10) vs <5-year survivors (n = 40), the former had 
higher ORR (100% vs 30%), longer axitinib therapy duration (median 5.8 years vs 0.67 
years), and better baseline PS (80% vs 53% with PS 0) but were of similar median age (57 vs 
60), gender (80% vs 75% males), and risk factors (50% vs 40% with zero MSKCC factors). 
Subsequently, the Phase 2 Study (Protocol A4061035) in Japanese patients with advanced 
RCC who were refractory to first line cytokine containing regimen was conducted. 26  64 
patients were enrolled in this study.  Based on the results from IRC, confirmed partial 
response was observed in 32 patients, and ORR was 50.0%.  In addition, median PFS was 11 
months as of data cutoff date (February 26, 2010). 
1.1.3.2. Sorafenib- and Sunitinib-Failure mRCC Study 
The third Phase 2 study (Protocol A4061023) enrolled 62 patients with mRCC who were 
refractory to sorafenib treatment. In addition to prior sorafenib, most of the patients received 
prior sunitinib and (or) other drugs before enrollment in this study. The analysis of all 62 
evaluable patients indicates 14 PRs (23%) and a median PFS of 7.4 months.  The median 
PFS for the 14 patients who failed both sunitinib and sorafenib was 7.1 months.27 
1.1.4. Comparative Effectiveness Phase III Study of Axitinib in second line mRCC 
The primary objective of this pivotal Phase 3 (AXIS) study was to compare the PFS of 
patients with mRCC receiving axitinib vs another TKI, sorafenib, following failure of 1 prior 
systemic first-line regimen.28  The secondary objectives were to compare the OS and ORR of 
patients in each arm, evaluate the safety and tolerability of axitinib, estimate the duration of 
response (DR) of patients in each arm, and compare the FACT-Advanced Kidney Cancer 
Symptom Index (FKSI) and EuroQoL-5D (EQ-5D). 
Between 15 September 2008 and 23 July 2010, a total of 723 patients with mRCC were 
randomized into this Phase 3 study, treated with either axitinib or sorafenib, and were 
followed for safety and efficacy. Enrolled patients were ≥18 years old, had histologically 
confirmed mRCC, had an ECOG PS of 0 or 1, and had failed 1 prior systemic, first-line 
regimen, which must have contained 1 or more of the following: sunitinib, bevacizumab + 
IFN-α, temsirolimus, or cytokine(s). Demographic and baseline characteristics were well 
balanced between both treatment arms. 
The study enrolled 361 patients in the axitinib arm and 362 in the sorafenib arm. Based on 
the  blinded IRC review of the overall analysis, the median PFS was 6.7 months (95% CI 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 17 
[6.3, 8.6]) in the axitinib arm and 4.7 months (95% CI [4.6, 5.6]) in the sorafenib arm, with a 
hazard ratio of 0.665 (95% CI [0.544, 0.812]) and p-value of <0.0001 (1-sided).  
In the subgroup of 251 patients who received prior treatment with cytokines (126 in the 
axitinib arm and 125 in the sorafenib arm), the median PFS in the axitinib arm was 12.1 
months (95% CI [10.1, 13.9]) compared with 6.5 months (95% CI [6.3, 8.3]) in the sorafenib 
arm, with a hazard ratio of 0.464 (95% CI [0.318, 0.676]) and a p-value of <0.0001 (1-sided). 
The sorafenib control arm replicated prior Phase 3 sorafenib data (median PFS of 5.5 
months) in a cytokine-refractory population.  In the subgroup of 389 patients who had 
received prior treatment with sunitinib-containing regimen (194 in the axitinib arm and 195 
in the sorafenib arm), the median PFS in the axitinib arm was 4.8 months (95% CI [4.5, 6.4]) 
compared with 3.4 months (95% CI [2.8, 4.7]) in the sorafenib arm, with a hazard ratio of 
0.741 (95% CI [0.573, 0.958]) and a p-value of 0.0107 (1-sided). The study enrolled only 59 
patients who received prior treatment with bevacizumab-containing regimen (29 in the 
axitinib arm and 30 in the sorafenib arm) and 24 patients who received prior treatment with 
temsirolimus-containing regimen (12 in the axitinib arm and 12 in the sorafenib arm). Due to 
small numbers of patients in these subgroups, no firm conclusions can be made.  
Figure 2 Kaplan-Meier Curve for Progression-Free Survival by Independent 
Assessment for the Overall Population 
 
 
Since only a total of 223 patients (approximately 30%) had died as of the data cutoff date (31 
August 2010), the data for OS are not mature and likely to change with further followup.  As 
of the data cutoff date, the median OS was not reached in the axitinib arm and was 18.9 
months in the sorafenib arm, with a hazard ratio of 1.008 with a 95% CI of (0.774, 1.313) 
and a 1-sided p-value of 0.525. Further follow-up of OS is continuing.  
Table 1 presents adverse reactions reported in patients who received axitinib or sorafenib:  
Axitinib 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 18 
Table 1 
Adverse Reaction (Phase III study) 
Adverse Reaction a 
Axitinib 
Sorafenib 
N=359 
N=355 
All Grades 
b 
Grade 3/4 
All Grades 
b 
Grade 3/4 
% 
% 
% 
% 
Diarrhea  
55  
11  
53  
7  
Hypertension  
40  
16  
29  
11  
Fatigue  
39  
11  
32  
5  
Decreased appetite 
34  
5  
29  
4  
Nausea  
32  
3  
22  
1  
Dysphonia  
31  
0  
14  
0  
Palmar-plantar erythrodysesthesia syndrome  
27  
5  
51  
16  
Weight decreased  
25  
2  
21  
1  
Vomiting  
24  
3  
17  
1  
Asthenia  
21  
5  
14  
3  
Constipation  
20  
1  
20  
1  
Hypothyroidism  
19  
<1  
8  
0  
Cough  
15  
1  
17  
1  
Mucosal inflammation  
15  
1  
12  
1  
Arthralgia  
15  
2  
11  
1  
Stomatitis  
15  
1  
12  
<1  
Dyspnea  
15  
3  
12  
3  
Abdominal pain  
14  
2  
11  
1  
Headache  
14  
1  
11  
0  
Pain in extremity  
13  
1  
14  
1  
Rash  
13  
<1  
32  
4  
Proteinuria  
11  
3  
7  
2  
Dysgeusia  
11  
0  
8  
0  
Dry skin  
10  
0  
11  
0  
Dyspepsia  
10  
0  
2  
0  
Pruritus  
7  
0  
12  
0  
Alopecia  
4  
0  
32  
0  
Erythema  
2  
0  
10  
<1  
a
Percentages are treatment-emergent, all-causality events  
b 
National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 19 
1.2. Rationale 
The axitinib response rate in cytokine-refractory patients is higher than reported response 
rates with cytokines or chemotherapeutics in the second-line setting.  Additionally, axitinib 
response rates in the second-line setting are better than response rates reported in the 
first-line setting with cytokines or chemotherapeutics alone or in combination.  The 5-year 
survival rate was 20.6% (95% CI, 10.9–32.4%) in patients with mRCC who were refractory 
to cytokine treatment.  Axitinib demonstrated a significantly longer PFS and higher ORR vs 
sorafenib with an acceptable safety profile as second-line therapy for mRCC.  Axitinib was 
approved by US Food and Drug Administration (FDA) in January 2012 with an indication 
for the treatment of advanced RCC after failure of one prior systemic therapy.  Axitinib was 
also approved in Japan, Korea and other countries in 2012 for the same indication.  The 
efficacy and safety of axitinib in patients with mRCC support further clinical study to pursue 
clinical benefits of adjuvant axitinib treatment for patients at high risk of recurrent RCC after 
nephrectomy. 
Risk stratification has become increasingly important in the management of patients newly 
diagnosed with RCC.  Tumor stage is currently the principal prognostic factor for patients 
with RCC.  Although various risk stratification systems have been described, none of them 
has been accepted as the standard of care.  This study aims to recruit those patients who are 
at a potentially relatively increased risk of disease recurrence.  Therefore, the target patients 
in this study are able to be considered patients at high risk of recurrent RCC. 
According NCCN Guidelines v1.2014, adjuvant treatment after nephrectomy currently has 
no established role in patients with renal cell cancer who have undergone a complete 
resection of their tumor. No systemic therapy has yet been shown to reduce the likelihood of 
relapse. Randomized trials comparing adjuvant interferon alpha or high-dose interleukin (IL-
2) or cytokines combinations with observation alone in patients who had locally advanced, 
completely resected RCC showed no delay in time to relapse or improvement in survival 
with adjuvant therapy. Observation remains standard care after nephrectomy, and eligible 
patients should be offered enrolled in randomized clinical trials. 
Without an established adjuvant treatment for patients with high risk of recurrence of their 
renal cell cancer after nephrectomy and observation or participation in clinical study as 
recommended standard; several placebo-controlled, randomized, double blind studies are 
currently ongoing in this indication (http://clinicaltrials.gov), which is ethically justifiable 
and necessary to meet regulatory standards for drug approval. 
2. TRIAL OBJECTIVES 
2.1. Primary Objective 
• To demonstrate an improvement in disease free survival (DFS) in patients at high risk 
of recurrent RCC randomly assigned to adjuvant axitinib (Arm A) vs. Placebo (Arm 
B) after nephrectomy. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 20 
2.2. Secondary Objectives 
• Compare OS associated with Arm A to that associated with Arm B 
• Assess safety/toxicity profile of administration of axitinib 
3. TRIAL DESIGN 
This is a prospective, randomized, double-blind placebo controlled Phase 3 trial of oral 
axitinib starting at 5 mg twice daily vs. placebo given for up to 3 years, with a minimum of 1 
year. The dose may be increased or decreased depending on individual patient tolerance of 
axitinib.   
A total of approximately 700 patients will be randomized in a 1:1 ratio between axitinib vs 
placebo.  Patients should begin study treatment within 7 days after randomization.  
Randomization will occur no sooner than 4 weeks post-nephrectomy and no later than 12 
weeks post-nephrectomy. 
Follow-up for recurrence (distant or local recurrence of RCC) or occurrence of a secondary 
malignancy (occurrence of a second primary cancer other than RCC) must be collected at 
each clinic visit as per protocol.  All patients will be followed up (regardless of the duration 
of treatment) until the time for the final analysis, every 16 weeks for the first 3 years from 
initiation of study treatment (also, at the end of treatment) and every 6 months thereafter for 
the remainder of the follow-up period, by clinic visit (See Section 6.4 for further details). 
All patients will be followed up for OS status (regardless of the duration of treatment) every 
16 weeks until the time for final DFS analysis.  Survival status can be ascertained by 
telephone contact.  At the time of final DFS analysis, OS results will be analyzed and 
summarized.  
Study Scheme: 
 
 
 
 
 
4. SUBJECT SELECTION 
The following eligibility criteria are designed to select patients for whom protocol treatment 
is considered appropriate.  All relevant medical and non-medical conditions should be taken 
into consideration when deciding whether this protocol is suitable for a particular patient.   
Arm A: axitinib 
Arm B: placebo 
Randomization 
Follow-up 
Treatment: Up to 3 years, with 
a minimum of 1 year 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 21 
4.1. Inclusion Criteria 
Patients must be newly-diagnosed RCC and treated by nephrectomy (complete or partial) and 
patients must meet all of the following inclusion criteria to be eligible for enrollment into the 
trial: 
1. Patients must have no evidence of macroscopic residual disease or metastatic disease. 
2. Male or female, age ≥18 years (age ≥20 years in Japan, Korea and Taiwan, age ≥18 
years and ≤ 65 years in India). 
3. Patients must be diagnosed with one of the following based on American Joint 
Committee on Cancer (AJCC) TNM staging version 2010 29, Eastern Collaborative 
Oncology Group (ECOG) performance status (PS). Any Fuhrman grades are eligible. 
The patient risk groups will be as follows. Group a will be closed for further 
enrollment, to keep the number of patients of groups b, c, and d with about 90% or 
more: 
a. 
pT2, pN0 or pNx, M0 and ECOG PS 0-1 
b. pT3, pN0 or pNx, M0 and ECOG PS 0-1 
c. 
pT4, pN0 or pNx, M0 and ECOG PS 0-1 
d. Any pT, pN1, M0 and ECOG PS 0-1 
 
4. Patients must have histologically confirmed preponderant, defined as >50%, clear cell 
RCC. 
5. Patients must not have received any previous systemic (includes chemotherapeutic, 
hormonal, or immunotherapeutic) treatment for RCC. 
6. Patients must not have received any previous anti-angiogenic treatment. 
7. Patients must have adequate organ function defined as:  
• Absolute neutrophil count (ANC) ≥1500 cells/mm3. 
• Platelets ≥75,000 cells/mm3. 
• Hemoglobin (Hgb) ≥9.0 g/dL. 
• AST and ALT ≤2.5 x upper limit of normal (ULN). 
• Total bilirubin ≤1.5 x ULN. 
• Serum creatinine (Scr) ≤1.5 x ULN or calculated creatinine clearance (Clcr) ≥30 
mL/min (by the Cockcroft-Gault equation*). 
* For males; the Cockcroft-Gault equation, using Scr : Clcr (mL/min) = (140 - 
Age in years) × weight (in kilograms) / [72 × Scr (in mg/dL)] 
The calculated Clcr should be multiplied by 0.85 to adjust for female gender. 
• Urinary protein <2+ by urine dipstick.  If dipstick is ≥2+ then a urine protein: 
urine creatinine ratio (UPC) should be done and the patient may enter only if UPC 
is < 2.0. 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 22 
8. At screening, no evidence of preexisting uncontrolled hypertension as documented by 
2 blood pressure (BP) readings taken at least 1 hour apart in the seated position after 
the patient has been sitting quietly for 5 minutes.  The systolic blood pressure (sBP) 
readings must be ≤140 mm Hg, and the diastolic blood pressure (dBP) readings must 
be ≤90 mm Hg.  Patients whose hypertension is controlled by antihypertensive 
therapies are eligible. 
9. Women of childbearing potential and men must use adequate contraception during 
the study and for 6 months after discontinuing or completing study treatment.  
Acceptable contraception for women include implants, injectables, combined oral 
contraceptives, intrauterine devices (IUDs), sexual abstinence, or a partner who has 
been vasectomized for at least 6 months.  Acceptable contraception for a male 
includes having had a vasectomy for at least 6 months, sexual abstinence, or condoms 
plus spermicide. 
10. Signed and dated informed consent document (ICD) indicating that the patient (or 
legally acceptable representative) has been informed of all pertinent aspects of the 
trial prior to enrollment. 
11. Willingness and ability to comply with scheduled visits, treatment plans, laboratory 
tests, and other study procedures. 
4.2. Exclusion Criteria 
Patients presenting with any of the following will not be included in the trial: 
1. Histologically undifferentiated carcinomas, sarcomas, collecting duct carcinoma, 
lymphoma, or patients with any metastatic renal sites. 
2. Active bleeding (other than menstrual bleeding) at randomization. 
3. Diagnosis of any non-RCC malignancy within the 5 years from date of 
randomization, except basal cell carcinoma, squamous cell skin cancer, or in situ 
carcinoma of the cervix uteri that has been adequately treated with no evidence of 
recurrent disease for 12 months. 
4. Any of the following within the 12 months prior to study drug administration:  
myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, 
symptomatic congestive heart failure, cerebrovascular accident or transient ischemic 
attack and 6 months for deep vein thrombosis or pulmonary embolism. 
5. Gastrointestinal abnormalities including: 
• inability to take oral medication  
• requirement for intravenous alimentation 
• prior surgical procedures affecting absorption including total gastric resection 
• treatment for active peptic ulcer disease in the past 6 months 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 23 
• active gastrointestinal bleeding, unrelated to cancer, as evidenced by 
hematemesis, hematochezia or melena in the past 3 months without evidence of 
resolution documented by endoscopy or colonoscopy 
• malabsorption syndromes 
• chronic diarrhea that persists at Grade 3 or 4 despite maximal medical therapy 
6. Major surgery <4 weeks, or radiation theapy <2 weeks, of starting the study treatment 
or incomplete healing of surgical or superficial wounds. 
7. Current use or anticipated need for treatment with drugs that are known potent 
CYP3A4/5 inhibitors (eg, grapefruit juice, ketoconazole, itraconazole, clarithromycin, 
atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). 
8. Current use or anticipated need for treatment with drugs that are known CYP3A4/5 or 
CYP1A2 inducers (eg, rifampin, dexamethasone, phenytoin, carbamazepine, 
rifabutin, rifapentin, phenobarbital, and St. John’s wort). 
9. Active seizure disorder or evidence of brain metastases, spinal cord compression, or 
carcinomatous meningitis. 
10. A serious uncontrolled medical disorder or active infection that would impair their 
ability to receive study treatment. 
11. Known human immunodeficiency virus (HIV) or acquired immunodeficiency 
syndrome (AIDS)-related illness. 
12. Pregnancy or breastfeeding.  Urinary pregnancy test should be performed by sites on 
female patients who have not experienced at least one consecutive year of 
amenorrhea without ovarian dysfunction, or have been taking hormonal therapy, or 
have been rendered surgically sterile.  If positive, serum pregnancy test should be 
performed at central laboratories. All female patients of childbearing potential must 
have a negative pregnancy test within the 14 days prior to date of randomization.  
(Definition of surgical sterilization: patients who underwent hysterectomy or bilateral 
oophorectomy, or bilateral tubal ligation) 
13. Dementia or significantly altered mental status that would prohibit the understanding 
or rendering of informed consent and compliance with the requirements of this 
protocol. 
14. Other severe acute or chronic medical or psychiatric condition or laboratory 
abnormality that may increase the risk associated with study participation or study 
drug administration, or may interfere with the interpretation of study results, and in 
the judgment of the investigator would make the patient inappropriate for entry into 
this study. 
15. Receipt of any investigational oncology or, approved or investigational 
anti-angiogenic agent prior to study entry. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 24 
16. Current treatment on another therapeutic clinical trial.  Supportive care trials or 
non-treatment trials, eg, Patient Reported Outcomes (PRO) methods studies, are 
allowed. 
4.3. Randomization Criteria  
Patients must be randomized no earlier than 4 weeks and no later than 12 weeks after 
nephrectomy and treatment should be started within 7 days after randomization.  Patient 
eligibility must be confirmed by independent review committee (IRC) assessment of imaging 
by a sponsor designated center prior to randomization. 
Patients must be randomized based on the assessment by the IRC when there is a discrepancy 
between the local and the IRC imaging review. 
A centralized system will be used to assign patient numbers and randomize patients into 
blinded study drug: axitinib, or blinded placebo identical in appearance to the active study 
drug. 
After a patient has provided written informed consent and has completed the necessary 
screening assessments, the clinical site must contact a centralized internet/telephone 
registration system (IWRS/IVRS), to enroll the patient into study. 
For those patients who failed screening, the reason for screen failure should be entered in the 
source documentation.  The following information should also be collected in the source 
documents: Patient age, sex, ECOG PS, tumor size (eg, T1, T2, T3), nodal disease (Yes/No), 
metastatic disease (Yes/No), histological type (eg, clear cell).  
At the time of registration, the clinical site staff must provide site and patient identifiers and 
demographic information.  The registration system will assign a unique patient identification 
number.  The system will also be used to assign blinded study drug bottles.  Patients will be 
randomized to one of two arms: 
Arm A: axitinib 5 mg BID taken orally (doses should be taken approximately 12 hours apart 
continuous dosing) 
Arm B: Placebo tablets BID taken orally  
Patients will be stratified by: 
1. Risk group 
a. 
pT2, pN0 or pNx, M0 and ECOG PS 0-1 
b. pT3, pN0 or pNx, M0 and ECOG PS 0-1 
c. 
pT4, pN0 or pNx, M0 and ECOG PS 0-1 
d. Any pT, pN1, M0 and ECOG PS 0-1 
2. Country 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 25 
Eligible patients will be randomized in a 1:1 ratio to one of the two treatments using the 
registration system.  Patients in risk group a or b will be stratified by risk group and by 
country.  Patients in risk group c or d will be stratified by risk group only.   
Randomization shall continue until a minimum of 10% of subjects are represented in this 
study from groups c and d.  Risk group a will be closed for from further enrollment, to keep 
the number of patients of risk groups b, c, and d with about 90% or more. 
4.4. Life Style Guidelines  
During the study female patients of childbearing potential must take precautions to prevent 
pregnancy since the effects on the fetus are unknown.  Male patients with partners of 
childbearing potential must take precautions to prevent pregnancy of the partner since the 
effects of these drugs on sperm are unknown.  These restrictions should remain in force for 6 
months from the last dose of investigational agent.  Drug interaction studies with oral 
contraceptives have not been performed, so barrier methods of contraception or abstinence 
should be considered.  Adequate contraception should be discussed with the investigator 
before the treatment start and should be in agreement with local law. 
5. TRIAL TREATMENTS 
5.1. Allocation to Treatment 
Axitinib for up to 3 years, with a minimum of 1 year until recurrence, occurrence of a 
secondary malignancy, significant toxicity, or withdrawal of consent. 
OR 
Placebo for up to 3 years, with a minimum of 1 year until recurrence, occurrence of a 
secondary malignancy, significant toxicity, or withdrawal of consent. 
5.2. Breaking the Blind  
At the initiation of the trial, the trial site will be instructed on the method for breaking the 
blind.  The method will be an electronic process.  Blinding codes should only be broken in 
emergency situations for reasons of patient safety, or if the patient has a confirmed 
recurrence or occurrence of a secondary malignancy with limited alternative treatment option 
and knowledge of study drug is required to facilitate further treatment decision. For those 
with suspected recurrence, the site must await results from the Independent Review 
Committee (IRC). The decision to break the blind must be approved by the Sponsor prior to 
doing so. When the blinding code is broken, the reason must be fully documented in the site 
source document. 
5.3. Drug Supplies 
In this clinical trial, study drug or investigational agent refers to axitinib and placebo. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 26 
5.3.1. Formulation and Packaging 
Axitinib will be supplied as 1 mg and 5 mg film-coated tablets for oral administration in 
light-protecting bottles.  Placebo will match all dose formulations.  
5.3.2. Preparation and Dispensing 
Axitinib and matching placebo will be dispensed as tablets in opaque plastic bottles to protect 
the compounds from light.  Axitinib is a hazardous drug (due to possible reproductive 
toxicity), and should be handled according to the recommended procedures described in the 
current edition of the American Society of Hospital Pharmacists (ASHP), Technical 
Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs, American Hospital 
Formulary Service (AHFS) Drug Information (1999) and its references.  Procedures 
described in each institution’s pharmacy or hospital standard operating procedure manual 
should be followed when handling hazardous drugs. 
5.3.3. Administration 
Patients will receive blinded study drug: Axitinib or blinded matching placebo identical in 
appearance to the active study drug twice daily. 
Patients will receive a starting dose of 5 mg of axitinib or placebo twice daily taken orally 
with or without food.  Dose adjustments, including dose increase or dose reduction will be 
based on adverse events experienced by the individual patient.  Study drug will be taken 
beginning on Day 1 of the study.  Doses should be taken approximately 12 hours apart 
continuous dosing.  Patients should be instructed to take their doses at approximately the 
same times each day.  If a patient vomits or misses a dose, an additional dose should not be 
taken. The next prescribed dose should be taken at the usual time.  Missed or vomited doses 
must be indicated in the source documents and Case Report Forms (CRFs). Study drug will 
be administered in cycles of 4 weeks in duration. 
Patients who tolerate axitinib or placebo with no adverse events related to study drug above 
CTCAE Grade 2 for a consecutive 2-week period may have their dose increased by one dose 
level to maximum of 10 mg BID (unless the patient’s BP is >150/90 mm Hg or the patient is 
receiving antihypertensive medication).  The clinical judgment of the treating investigator 
should be exercised in titrating axitinib/placebo dose. 
Patients experiencing drug reaction should undergo dose modification as recommended in 
Section 5.3.4. 
Once the dosage is reduced, it can be uptitrated again. 
Concomitant medications that are known to substantially inhibit the enzyme, CYP3A4/5, 
should be avoided as much as medically possible on this study as in Section 5.5.1.  If a strong 
CYP3A4/5 inhibitor must be co-administered, based on investigator judgment, the dose of 
study drug (axitinib/placebo) should be decreased by one or more dose levels. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 27 
Table 2 
Available Axitinib/Placebo Dose Levels 
Dose Level 
Dose 
Dispensed As 
+2 
10 mg BID 
2 X 5 mg Tablets BID  
+1 
7 mg BID 
1 X 5 mg Tablet  BID + 2 X 1mg Tablets BID 
0 (Starting Dose) 
5 mg BID 
1 X 5 mg Tablet BID (twice daily) 
-1 
3 mg BID 
3 X 1 mg Tablets BID     
-2 
2 mg BID 
2 X 1 mg Tablets BID     
-3 
1 mg BID 
1 X 1 mg Tablet BID 
 
5.3.4. Dose Interruption and Reduction 
Adverse events and other symptoms will be graded according to the current CTCAE v4.0 
(See URL:  http://ctep.cancer.gov/reporting/ctc.html). 
5.3.4.1. Management of Axitinib/Placebo-Related Adverse Events 
This section contains management of adverse events except hypertension and proteinuria 
which are discussed in subsequent sections. 
The criterion for dose modification for study-drug-related adverse events is summarized in 
the table below: 
Table 3 
Criteria for Dose Modification for Axitinib/Placebo – Related Adverse 
Events Other Than Hypertension Or Proteinuria 
Related Adverse Events 
Intervention 
Grade 1 
Continue at same dose level. 
Grade 2*  
Continue at same dose level or decreased dose to one 
lower dose level.a) 
Grade 3* 
Interrupt dosing; re start at one or two lower dose level 
as soon as improvement to CTCAE Grade ≤1 or 
baseline.b)  Discontinue dosing in case of grade 3 
persisting for ≥ 2 weeks or grade 3 despite dose 
reduction to 1 mg BID. 
Grade 4 or RPLS** 
Discontinue dosing 
* Patients who have a grade 3 arterial event, grade 3 hemorrhagic event, grade 3 perforation/fistula, grade 3 
palmar-planter erythrodysesthesia syndrome (PPE), or persistent grade 2 PPE despite dose reduction to 1 mg 
BID, should be discontinued dosing.  
** Treatment interruption for patients with signs/symptoms of reversible posterior leukoencephalopathy (RPLS). 
RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and 
other visual and neurologic disturbances. Mild to severe hypertension may be present. Magnetic resonance 
imaging is necessary to confirm the diagnosis of RPLS. In case of confirmed diagnosis discontinue 
permanently. 
a) Dose may be decreased to one lower dose level if the investigator considers it is difficult to continue 
treatment at same dose level. 
b) Dose may be decreased to two lower dose level if the investigator considers it is difficult to continue 
treatment at one lower dose level. 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 28 
Dose may also be interrupted or decreased at the discretion of the investigator even if none of 
the above criteria applies. 
Guidelines for dose reductions for specific adverse events are provided in the following 
sections. 
5.3.4.2. Axitinib/Placebo Dose Reduction for Hypertension 
Patients treated with axitinib/placebo will be issued blood pressure cuffs (provided by 
Sponsor) for home monitoring and instructed to measure their blood pressure prior to taking 
each dose of study drug (twice daily) for the first 3 months, and once a week thereafter.  
Following dose modification of study drug or anti-hypertensive medication, or changes of 
anti-hypertensive medication, patients must restart blood pressure measurements prior to 
taking each dose of study drug for the first 3 months and once a week thereafter.  All BP 
measurements will be recorded in a diary by the patient themselves and brought to the nurse 
or study coordinator at each clinic visit.  Patients should be instructed by the study staff to 
contact their investigator immediately for guidance if their sBP rises above 150 mm Hg, or 
dBP rises above 100 mm Hg, or if they develop symptoms perceived to be related to elevated 
BP (eg, headache, visual disturbance).  See below for dose modifications for hypertension. 
New or additional antihypertensive therapy (See Section 5.5.1, Concomitant Medication) 
should be started if 2 BP readings, taken at site and separated by at least 5 minutes in the 
seated position after the patient has been sitting quietly for 5 minutes, show the following: 2 
sBP readings >150 mm Hg or 2 dBP readings  >100 mm Hg.  Alternately, the dose of 
existing antihypertensive medication(s) may be increased.  If the patient is already on 
maximal antihypertensive treatment, the axitinib/placebo dose should be reduced by 1 dose 
level. 
Patients who have 2 sBP readings, separated by at least 5 minutes, greater than 160 mm Hg, 
or 2 dBP readings, separated by at least 5 minutes in the seated position after the patient has 
been sitting quietly for 5 minutes, greater than 105 mm Hg, will have treatment with 
axitinib/placebo interrupted.  (Note: if axitinib/placebo is interrupted, patients receiving 
antihypertensive medications should monitor closely for hypotension and restart 
axitinib/placebo at one lower dose level as soon as BP is ≤150/100 mm Hg.  Plasma half-life 
of axitinib is 2-4 hours and BP usually decreases within 1-2 days following dose 
interruption.)  Treatment with axitinib/placebo should be restarted at 1 lower dose level as 
soon as the sBP reduces to less than or equal to 150 mm Hg and the dBP reduces to less than 
or equal to 100 mm Hg. 
Patients who develop recurrent systolic hypertension (2 BP readings separated by at least 
5 minutes show sBP >150 mm Hg) or recurrent dBP >100 mm Hg following previous 
axitinib/placebo dose reduction should undergo another dose reduction by one dose level.   
Patients removed from treatment for intolerable toxicity should still be followed with regular 
tumor assessments until recurrence or occurrence of a secondary malignancy or start of new 
treatment, and for survival thereafter. Guidance on dose interruption and reduction for 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 29 
hypertension is summarized in the table below.  The BP readings stated in this table is based 
on BP measurement taken at the site. 
Table 4 
 Hypertension Management Plan for Axitinib/Placebo 
Degree of Blood Pressure Elevation 
Management 
Systolic Blood Pressure 
 
 
OR 
Diastolic Blood Pressure 
 
If not on maximal antihypertensive 
treatment, institute new or additional 
antihypertensive medication* and 
maintain dose of axitinib/placebo.  
If on maximal antihypertensive 
treatment, reduce axitinib/placebo to 
one lower dose level. 
2 BP readings separated by at 
least 5 minutes show sBP 
>150 mm Hg 
2 BP readings separated by 
at least 5 minutes show dBP 
>100 mm Hg 
2 BP readings separated by at 
least 5 minutes show sBP 
>160 mm Hg  
 
 
OR 
2 BP readings separated by 
at least 5 minutes show dBP 
>105 mm Hg  
Interrupt dosing**; 
Adjust antihypertensive medication; 
As soon as BP is less than or equal to 
150/100 mm Hg, restart 
axitinib/placebo at one lower dose 
level.   
Recurrent hypertension 
following previous dose 
reduction (2 BP readings 
separated by at least 5 
minutes show sBP >150 mm 
Hg) 
 
OR 
Recurrent dBP >100 mm Hg 
(2 BP readings separated by 
at least 5 minutes) following 
previous dose reduction 
Repeat axitinib/placebo dose reduction 
by one lower dose level.   
* If no contraindication – consider preferred anti-hypertensive monotherapy: Angiotensin system inhibitors 
(ASI) or preferred combination anti-hypertensive therapy: Diuretic and angiotensin system inhibitor [please 
check local guidelines] 
Based on current international guidelines: ASI- Angiotensin Converting Enzyme (ACE) Inhibitor or 
Angiotensin receptor blocker; Diuretics; Beta-blocker or Calcium antagonists: All suitable and recommended 
for initiation + maintenance of antihypertensive treatment as monotherapy or in some combinations. Additional 
aspects for consideration within this study:  
- No drug-drug interaction between axitinib and ASI expected (e.g. enalapril, captopril, losartan, valsartan). 
Retrospective data [McKay et al.J Clin Oncol 32, 2014 (suppl 4; abstr 437)] indicate that ASI may improve 
outcome in patients with renal cell cancer. 
- No interference between axitinib and beta blockers (atenolol, metoprolol, labetalol), or diuretics 
(hydrochlorothiazide, furosemide) expected. 
- Not first choice based on potential interference with axitinib plasma level: calcium channel blockers 
(verapamil) and to a lesser extent nifedipine, nicardipine, and diltiazem.  
- Other calcium channel blockers (amlodipine, bepridil, felodipine) are less likely to interfere with axitinib 
plasma levels. 
** If axitinib/placebo is interrupted, patients receiving antihypertensive medications should be monitored 
closely for hypotension. Plasma half-life of axitinib is 2-4 hours and BP usually decreases within 1-2 days 
following dose interruption. 
 
5.3.4.3. Axitinib/Placebo Dose Reduction for Proteinuria 
• If dipstick shows ≥2+ proteinuria, perform UPC.  Dosing may continue while waiting for 
test results. 
• If UPC < 2.0 is reported, continue dosing at the same dose level. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 30 
• If UPC ≥ 2.0 is reported, hold dosing and repeat UPC (interval at investigator discretion) 
until UPC is < 2.0. Restart axitinib/placebo at the same dose or one lower dose level at 
discretion of the investigator.  Repeated UPC can be performed during treatment 
interruption at the site laboratory. 
• If UPC ≥ 2 despite dose reduction to 1 mg BID, discontinue dosing. 
Patients removed from treatment for intolerable toxicity should still be followed with regular 
tumor assessments until recurrence or occurrence of a secondary malignancy or start of new 
treatment, and for survival thereafter. 
5.3.4.4. Axitinib/Placebo Dose Interruption for Surgery or Surgical Procedures 
If a major surgery or an invasive intervention (eg, endoscopy) is required, treatment with 
axitinib/placebo must be interrupted at least 24 hours before the procedure and the patient BP 
should be monitored closely for hypotension.  Depending on the investigators assessment 
patients may resume axitinib/placebo 7 days after surgery/invasive intervention, assuming 
wound has completely healed and no wound healing complications (eg, delayed healing, 
wound infection or fistula). 
5.3.5. Compliance 
Patients will maintain diaries to include missed or changed doses.  Pill counts on returned 
study drug bottles should be performed. 
5.4. Drug Storage and Drug Accountability 
Axitinib/placebo will be supplied for the study.  Study drug will be shipped to the study sites. 
The investigator, or an approved representative (eg, pharmacist), will ensure that all 
axitinib/placebo is stored in a secured area, under recommended storage conditions and in 
accordance with applicable regulatory requirements.  Drug should be stored at controlled 
room temperature (ie, 15-30°C) and protected from light and moisture.  
To ensure adequate records, all axitinib/placebo will be accounted for in the CRFs and drug 
accountability inventory forms as instructed by sponsor.  Unless otherwise authorized by 
sponsor, at the end of the clinical trial all drug supplies unallocated or unused by the patients 
must be returned to sponsor or its appointed agent (eg, a contract research organization). 
Axitinib is considered a hazardous drug (due to possible reproductive toxicity), and should be 
handled according to the recommended procedures described in the current edition of the 
ASHP, Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs, AHFS 
Drug Information (1999) and its references.  Procedures described in each institution’s 
pharmacy or hospital standard operating procedure manual should be followed when 
handling hazardous drugs. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 31 
5.5. Prior/Concomitant Therapy 
5.5.1. Prior/Concomitant Medication 
No other chemotherapy or experimental anticancer medications will be permitted while the 
patient is on study.  Any disease requiring other forms of systemic anticancer therapy will be 
cause for discontinuation from study treatment.   
Patients may receive loperamide or other medications for treatment or prophylaxis of 
potential diarrhea.  Anti-inflammatory or narcotic analgesics may be offered as needed.  
Patients with fever or infection may undergo diagnostic tests and treated with antibiotics as 
appropriate and may receive therapeutic colony-stimulating factors as appropriate.  
Erythropoietic agents such as epoetin or darbepoetin may be used at the discretion of the 
treating investigator.  Packed red blood cell and platelet transfusions should be administered 
as clinically indicated.  Low-dose oral steroids (defined as <5 mg per day prednisone or 
equivalent), short course of oral steroids (defined as < 5 consecutive days or topical or 
inhaled steroids at any dose) may be taken during the study.   
Patients who need to be on anticoagulant therapy before or during study treatment should be 
treated with low molecular weight heparin. If low dose heparin cannot be administered, the 
administration of coumadin or other coumarin derivatives or other anti-coagulants may be 
allowed; however, appropriate monitoring for bleeding risk including prothrombin 
time/international normalized ratio (PT/INR) should be performed. 
In vitro studies with human liver microenzymes and recombinant CYP enzymes indicated 
that axitinib metabolism was primarily mediated by the drug-metabolizing enzyme 
CYP3A4/5, and to a lesser extent by CYP1A2.  Additionally, the drug also undergoes 
N-glucuronidation in liver microsomes of some species.  Clinically, there is likelihood that 
axitinib plasma concentrations may be increased in the presence of co-administered potent 
inhibitors of the CYP3A4/5 and glucuronosyltransferase enzymes.  In a healthy volunteer 
study, ketoconazole, a potent CYP3A4/5 inhibitor, produced a 2-fold increase in plasma 
exposure and a 1.5-fold increase in peak plasma concentration of axitinib. Therefore a 
potential exists for drug-drug interactions with CYP3A4/5 inhibitors such as grapefruit juice, 
ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, 
ritonavir, saquinavir, and telithromycin.  Caution should be exercised in patients receiving 
axitinib in combination with these and other potent CYP3A4/5 inhibitors until appropriate 
clinical drug interaction studies are performed.  If a strong CYP3A4/5 inhibitor must be co-
administered, based on investigator judgment, the dose of study drug (axitinib/placebo) 
should be decreased by one or more dose levels. 
Axitinib metabolism may be induced in patients taking CYP3A4/5 or CYP1A2 inducers 
(rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, 
and St. John’s wort) and this may reduce axitinib plasma concentrations.  Patients who 
require concomitant treatment with potent CYP3A4/5 or CYP1A2 inducers are not eligible 
for the study.  Since CYP1A2 is also known to be induced in chronic smokers, there is 
likelihood that axitinib plasma concentrations may be reduced in these individuals.  (Note: 
these patients are not excluded from enrolment, however.) 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 32 
The ability of axitinib to increase concentrations of coadministered drugs was also 
investigated in studies with human liver microsomes.  At expected therapeutic plasma 
concentrations (0.01 to 1.0 μg/mL), axitinib appears most likely to inhibit the drug 
metabolizing enzymes CYP1A2 and CYP2C8, 2 enzymes not frequently observed as 
predominant drug metabolizing enzymes.  Theophylline, and tacrine are among the few drugs 
whose plasma concentrations are likely to be increased by axitinib. 
Axitinib is highly bound to proteins in human plasma (99.5% bound at concentrations 
between 0.2 to 20 μg/mL).  Therefore, drug interactions with other agents that are also highly 
bound to plasma proteins are a possibility. 
Axitinib is not likely to have drug-drug interactions with commonly used antihypertensive 
agents belonging to the class of ACE inhibitors including angiotensin II receptor antagonists 
(enalapril, captopril, losartan, valsartan), beta-blockers (atenolol, metoprolol, labetalol), or 
diuretics (hydrochlorothiazide, furosemide).  Within the class of calcium channel blockers, 
verapamil, and to a lesser extent nifedipine, nicardipine, and diltiazem have a potential for 
increasing axitinib plasma concentrations, due to CYP3A4/5 inhibition and should not be 
used as first choice in antihypertensive treatment.  Other calcium channel blockers 
(amlodipine, bepridil, felodipine) are less likely to raise axitinib plasma levels. 
The above information is based on preclinical data from studies using human and animal 
metabolizing enzyme systems.  
All prior/concomitant medications and blood products, as well as interventions (eg, analgesic 
use or paracentesis) received by patients from the time the patient has signed informed 
consent until 28 days after last treatment will be recorded on the CRF.  Anti-tumor therapy 
should be recorded even after 28 days after last treatment. 
5.5.2. Concomitant Radiotherapy 
Investigators are encouraged to await the result of the IRC assessment before making 
treatment decisions for patients who require palliative radiotherapy because of suspected 
recurrence or occurrence of a secondary malignancy unless clinical considerations require 
immediate intervention eg, in the case of brain metastases.  In the event that an investigator 
determines recurrence or occurrence of a secondary malignancy based on local imaging 
and/or local histo-/cytopathology reports, the patient must continue to receive tumor 
assessments until the IRC determines recurrence or occurrence of a secondary malignancy.  
6. TRIAL PROCEDURES 
6.1. Screening 
 
 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 33 
Figure 3 Screening Procedures 
 
 
 
 
 
 
6.1.1. Screening Procedures between Nephrectomy and Starting Treatment 
One rescreening is acceptable.  Patient with screening values/findings outside ranges 
described in the protocol may, at the discretion of the investigator, have one repeat 
determination performed and if the repeat value satisfies the criterion they may continue in 
the screening process. Only the specific out of range value/finding should be repeated (not 
the entire panel). 
a. Medical history including oncologic history, history of other disease processes (active 
or resolved), signs and symptoms, concomitant medications and treatments, illnesses 
and demographics. 
b. Local histopathology confirmation of eligibility is required. 
c. Pre-surgery images are requested, if available or whenever possible should be 
submitted for IRC review. 
d. ECOG PS ascertained at the time of nephrectomy (just prior to nephrectomy) is 
desired.   
e. Local and IRC review of tumor imaging including CT or MRI of the brain, chest, 
abdomen and pelvis and other applicable sites of disease.  CT scans are expected to 
be with intravenous and/or oral contrast.  CT or MRI of the chest, abdomen and 
pelvis must be performed at least 3 weeks after nephrectomy.  Results of the IRC 
assessment must be awaited before randomizing patients.  Thus, images should be 
submitted for IRC review before Week 8 post-nephrectomy to allow for return of the 
results before Week 12 and in the event a repeat scan is needed.  Brain CT or MRI 
within 12 weeks prior to randomization is acceptable regardless of whether it is 
before or after nephrectomy.  Bone scan (either Tc-99 or positron emission 
tomography (FDG-PET)) can be performed if clinically indicated. 
6.1.2. Screening Procedures Within 2 Weeks Prior to Randomization 
a. Physical examination of major body systems. 
Week 12 
Week 10 
Week 8 
Week 3 
Week 0 
*: IRC review of imaging to be returned within 2 weeks post submission of images. 
**: Randomization will occur no sooner than 4 weeks post-nephrectomy and no later than 12 weeks post-
nephrectomy. This figure shows the latest case after nephrectomy.  Study treatment should be started within 7 
days after randomization. 
 
Physical Exam, 
Body weight, height, 
Laboratory test, 
ECG, Vital 
Post- nephrectomy Imaging* 
Nephrectomy 
Randomization** 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 34 
b. Body weight, height and vital signs (temperature, 2 BP readings separated by at least 
1 hour, pulse rate). 
c. Laboratory tests. 
• Hematology: Hgb, white blood cell count (WBC), ANC, lymphocyte count and 
platelet count. 
• Chemistry: Total bilirubin, AST, ALT, alkaline phosphatase, albumin, total 
protein, LDH, sodium, potassium, chloride, calcium, phosphate, BUN/Urea, 
creatinine, glucose. 
• Urine dipstick for protein (patients with ≥2+ protein will have UPC). 
• Pregnancy test, if applicable. Urine pregnancy test will be conducted at sites for 
females of childbearing potential only. If positive, then serum test should be 
conducted at central laboratories. 
d. Triplicate 12 lead ECGs to be performed two weeks prior to randomization.  Three 
consecutive 12 lead ECGs (with a 10 second rhythm strip) will be collected at 
screening to determine the mean QTc interval. If the QTc interval is prolonged 
(>500msec), the ECG should be re-read by a cardiologist at the site for confirmation. 
e. Assessment of concomitant medications and treatments. 
f. Study Registration/Randomization. 
6.2. Trial Period 
For the purposes of this study, unscheduled assessments may occur coincident with safety 
events, early discontinuation of study treatment, early study termination, suspected 
recurrence, or suspected occurrence of the secondary malignancy between protocol-specified 
study visits. 
6.2.1. Treatment Procedures First Cycle 
6.2.1.1. Day 1 
The following procedures must be performed pre-dose. It is not necessary to repeat the Day 1 
procedures if treatment is not started on the same day as randomization: 
a. Physical Examination of major body systems. 
b. Body weight and vital signs (temperature, BP, pulse rate). Patients who have 2 sBP 
readings, separated by at least 5 minutes, greater than 140 mm Hg, or 2 dBP readings, 
separated by at least 5 minutes, greater than 90 mm Hg, will not start treatment.   
c. ECOG PS. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 35 
d. Thyroid function tests: TSH, free T3, free T4. 
e. Assessment of adverse events. 
f. Assessment of concomitant medications and treatments. 
6.2.1.2. Day 15 
Assessments should be performed via telephone contact or visit.  In case of telephone contact, 
only adverse events assessment should be performed. 
a. Physical Examination of major body systems. 
b. Body weight and vital signs (temperature, 2 BP readings separated by at least 5 
minutes, pulse rate). 
c. Thyroid function tests: TSH (Free T3 and free T4 should be performed for any patient 
who has an elevated TSH at Day1 or the previous visit.)  Hypothyroidism should be 
treated per standard medical practice to maintain euthyroid state with a normal TSH. 
d. Assessment of adverse events. 
e. Assessment of concomitant medications and treatments. 
6.2.2. Treatment Procedures Subsequent Cycles 
Assessments other than tumor imaging should be done at Day 1 of every cycle (4 weeks) 
until Cycle 5 Day 1, then every 8 weeks thereafter starting from Cycle 7 Day 1. 
a. Physical examination of major body systems. 
b. Body weight and vital signs (temperature, 2 BP readings separated by at least 5 
minutes, pulse rate). 
c. ECOG PS. 
d. Laboratory tests. 
• Hematology: Hgb, WBC, ANC, lymphocyte count and platelet count. 
• Chemistry: Total bilirubin, AST, ALT, alkaline phosphatase, albumin, total 
protein, LDH, sodium, potassium, chloride, calcium, phosphate, BUN/Urea, 
creatinine, glucose. 
• Urine Dipstick for protein (patients with ≥2+ protein will have UPC). 
• Thyroid function tests: TSH.  Hypothyroidism should be treated per standard 
medical practice to maintain euthyroid state with a normal TSH (TSH, Free T3 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 36 
and free T4 should be performed on the next visit for any patient who has an 
elevated TSH.). 
e. Tumor imaging including CT or MRI of the chest, abdomen, and pelvis should be 
performed every 16 weeks for the first 3 years from the initiation of study treatment.  
Additional imaging and/or local histo-/cytopathology confirmation, if clinically 
indicated, of potential disease sites should be performed whenever recurrence or 
occurrence of a secondary malignancy is suspected.  Brain CT or MRI with contrast 
or bone scan (confirmatory imaging in addition to bone scan may be required), if 
clinically indicated. 
f. Assessment of concomitant medications and treatments. 
g. Assessment of study drug compliance/accountability. 
h. Assessment of adverse events and tumor-related signs and symptoms. 
6.2.3. End of Study Treatment/Withdrawal from treatment Procedures 
At the end of the study or at withdrawal from treatment, the following procedures should be 
performed if they were not performed within 7 days of the end of the study or at withdrawal: 
a. Physical examination of major body systems. 
b. Body weight and vital signs (temperature, 2 BP readings separated by at least 5 
minutes, pulse rate). 
c. ECOG PS. 
d. Laboratory tests. 
• Hematology: Hgb, WBC, ANC, lymphocyte count and platelet count. 
• Chemistry: Total bilirubin, AST, ALT, alkaline phosphatase, albumin, total 
protein, LDH, sodium, potassium, chloride, calcium, phosphate, BUN/Urea, 
creatinine, glucose. 
• Urine Dipstick for protein (patients with ≥2+ protein will have UPC). 
• Thyroid function tests: TSH (Free T3 and free T4 should be performed for any 
patient who has an elevated TSH in the previous visit.) 
e. Tumor imaging including CT or MRI of the chest, abdomen, and pelvis and other 
applicable sites of disease.  Local histo-/cytopathology confirmation, if clinically 
indicated, of potential disease sites should be performed whenever recurrence or 
occurrence of a secondary malignancy is suspected.  Brain CT or MRI with contrast 
or bone scan if clinically indicated.  At the end of the study or at withdrawal, the 
tumor imaging should be performed if they were not performed within 8 weeks of the 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 37 
end of the study or at withdrawal for patients who discontinue treatment for reasons 
other than disease progression. 
f. Assessment of concomitant medications and treatments. 
g. Assessment of study drug compliance/accountability.  Patients must return all used 
and unused study drug bottles to the clinical site. 
h. Assessment of adverse events and tumor-related signs and symptoms. 
6.3. 28 Days Post Treatment Follow-Up Visit 
Patients should continue to be evaluated up to 28 days after the last dose of study drug.  At 
the post-treatment follow-up visit, the following procedures should be performed: 
• Assessment of adverse events and tumor-related signs and symptoms. 
• Assessment of concomitant medications and treatments. 
During this period, the outcome of adverse events with a date of onset during the study 
period should be reevaluated, and any new adverse events should be recorded.  All serious 
adverse events, and those non-serious adverse events assessed by the investigator as possibly 
related to study drug, should continue to be followed even after patient withdrawal from 
study.  These adverse events should be followed until they resolve, or until the investigator 
assesses them to be “chronic” or “stable”.   
6.4. Recurrence or occurrence of secondary malignancy and Survival Follow-Up 
Follow-up for recurrence or occurrence of a secondary malignancy must be collected at each 
clinic visit as per protocol.  All patients will be followed up (regardless of the duration of 
treatment) until the time for final analysis, every 16 weeks for the first 3 years from initiation 
of study treatment (also, at the end of treatment) and every 6 months thereafter for the 
remainder of follow-up period*.  If new anti tumor therapy is initiated for either recurrence 
or occurrence of a secondary malignancy at any time during this period, this and all other 
pertinent data obtained should be recorded on the appropriate CRFs.  The final analysis of 
primary endpoint (DFS) will be performed when approximately 245 DFS events have been 
reached. 
* Patients who complete 3-year treatment will be followed up for DFS every 6 months from 
the date of CT or MRI at the end of study treatment.   
Patients who withdraw from treatment before DFS events will be followed up for DFS every 
16 weeks from the date of CT or MRI at the withdrawal.  After 3 years from initiation of 
study treatment, CT or MRI for DFS will be performed every 6 months from the first scan 
date that is performed after more than 3 years from initiation of study treatment. 
All patients will be followed up for OS status (regardless of the duration of treatment) 
approximately every 16 weeks from DFS events until the time for final DFS analysis.  
Survival status can be ascertained by telephone contact. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 38 
6.5. Patient Withdrawal 
Patients may withdraw from the treatment/trial at any time at their own request, or they may 
be withdrawn at any time at the discretion of the investigator or sponsor for safety, 
behavioral, or administrative reasons.  If a patient does not return for a scheduled visit, every 
effort should be made to contact the patient.  In any circumstance, every effort should be 
made to document patient outcome, if possible.  The investigator should inquire about the 
reason for withdrawal, request that the patient return all unused investigational product(s), 
request that the patient returns for a final visit, if applicable, and follow-up with the patient 
regarding any unresolved adverse events. 
6.5.1. Withdrawal from treatment 
Patients will be withdrawn from treatment in the case of: 
• Recurrence or occurrence of a secondary malignancy.  Investigators are encouraged 
to await the result of the IRC assessment before making treatment decisions unless 
clinical considerations require immediate intervention eg, in the case of brain 
metastases;  
• Unacceptable toxicity; 
• Need for anticancer therapy not specified in the protocol; 
• Congestive heart failure; 
• Repeated noncompliance; 
• Patient becomes pregnant; 
• Patient lost to follow-up; 
• Patient choice to withdraw from treatment (follow-up permitted by patient) 
If patients require >2 consecutive weeks of dose interruption, a discussion should be made in 
consultation with the medical monitor. 
Data to be collected for the end of study treatment/withdrawal from treatment are described 
in the End of Study Treatment/Withdrawal from treatment Procedures section (Section 
6.2.3).  Patients will be followed up for at least 28 days after the last dose of study drug for 
adverse events and concomitant medications and treatments.  
6.5.2. Withdrawal from trial 
If the patient withdraws from the trial and also withdraws consent for disclosure of future 
information, no further evaluations should be performed and no additional data should be 
collected.  Sponsor may retain and continue to use any data collected before such withdrawal 
of consent. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 39 
7. ASSESSMENTS 
7.1. Efficacy Assessments 
Local and the IRC imaging tumor assessments are to be performed between week 3-8 post-
nephrectomy.  Brain CT or MRI within 12 weeks prior to randomization is acceptable 
regardless of whether it is before or after nephrectomy. 
During the trial, local and the IRC imaging tumor assessments will be performed (regardless 
of the duration of treatment) every 16 weeks during the first 3 years of study (also, at the end 
of treatment) and every 6 months thereafter until the time for final analysis, or recurrence or 
occurrence of a secondary malignancy, whichever comes first.  
Investigators are encouraged to await the result of the IRC assessment before making 
treatment decisions for patients who require palliative radiotherapy because of suspected 
recurrence or occurrence of a secondary malignancy unless clinical considerations require 
immediate intervention eg, in the case of brain metastases.  In the event that an investigator 
determines recurrence or occurrence of a secondary malignancy based on local imaging 
reviews and/or local histo-/cytopathology reports, the patient must continue to receive tumor 
assessments until the IRC determines recurrence or occurrence of a secondary malignancy.  
Local and IRC imaging assessments at screening and during the trial will include CT or MRI 
of the brain, chest, abdomen and pelvis, and other applicable sites.  Further imaging 
techniques e.g., bone scan, are to be performed as clinically indicated if metastases are 
present or suspected. 
For patients who present with findings suggestive of a tumor recurrence or secondary 
malignancy, histo-/cytopathological confirmation of the diagnosis should be obtained except 
in patients whose suspicious lesions are deemed by the investigator not to be amenable to 
biopsy.  Such available local histo-/cytopathology reports should be submitted to the IRC for 
review in cases for which there is site confirmation of recurrence or occurrence of a 
secondary malignancy in the absence of IRC imaging confirmation.  For patients with an 
isolated, suspected intracranial recurrence, histologic documentation of recurrence in 
surgically accessible lesions is highly recommended, but not required. For such patients, 
document the recurrent disease using MRI or CT if MRI is not generally available or is 
contraindicated. 
The diagnosis of a recurrence or occurrence of a secondary malignancy can be made only 
when the imaging, clinical or pathology findings meet at least one of the following 
acceptance criteria: 
Lung 
a. Positive cytology or histology. 
b. Imaging evidence of lesions felt to be consistent with metastases. 
c. Proof of neoplastic pleural effusion should be established by cytology or pleural 
biopsy. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 40 
Liver 
a. Positive cytology or histology. 
b. New focal defects on MRI or CT that are enlarging in size as documented by at least 
a 4-week interval. 
c. Proof of neoplastic abdominal ascites established by cytology or histology. 
Central Nervous System 
a. Positive brain CT or MRI. 
b. Positive cerebral spinal fluid (CSF) cytology. 
Subcutaneous and Lymph Node Recurrence 
a. Positive histology. 
b. Progressively enlarging solid mass or node(s) as evidenced by two CT or MRI 
separated by at least a 4-week interval. 
•Nodal lesions must have a short axis diameter ≥10 mm to be considered enlarged. 
Skeletal 
a. Positive radiographic study such as bone scan (confirmatory imaging in addition to 
bone scan may be required). 
b. For a solitary lesion or equivocal finding on imaging, a positive histology.  
Other Organs 
a. Histology/aspiration cytology. 
b. Progressively enlarging solid mass or node(s) as evidenced by two CT or MRI 
separated by at least a 4-week interval.  
•Nodal lesions must have a short axis diameter ≥10 mm to be considered enlarged. 
c. Urethral obstruction in the presence of a mass as documented on CT or MRI. 
Anything not meeting the above criteria should be considered unacceptable for evidence of 
recurrence or occurrence of a secondary malignancy and should not be an indication to alter 
protocol therapy. 
7.1.1. Primary Endpoint 
DFS is defined as the time interval from the date of randomization to the first date of 
recurrence (distant or local recurrence of RCC) or the occurrence of a secondary malignancy  
or death.  The primary DFS analysis will be based on assessments by the IRC.  IRC will 
review all imaging data.  Additionally, in cases for which there is site confirmation of 
recurrence or occurrence of a secondary malignancy in the absence of IRC imaging 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 41 
confirmation, available local histo-/cytopathology reports will also be reviewed by the IRC 
oncologist to determine confirmation of recurrence or occurrence of a secondary malignancy. 
Recurrence refers to relapse of the primary tumor in situ or at metastatic sites.  The date of 
recurrence or the occurrence of a secondary malignancy is defined as the date of the tumor 
scan or the date of collection of the histo-/cytopathological specimen (for patients who have 
site confirmation of recurrence or occurrence of secondary malignancy in the absence of IRC 
imaging confirmation) that demonstrated unequivocal recurrence or a secondary malignancy 
according to protocol criteria.  If both imaging and histo-/cytopatholigical confirmation of 
recurrence or sencondary malignancy are available, the earlier of the two dates will be 
considered.   
For patients with no DFS event, DFS time will be censored at the date of the last scan prior to 
the time for the analyses.  Patients alive who do not have post-baseline disease assessments 
will have their DFS times censored at randomization.  For patients receiving further 
anti-tumor therapy prior to recurrence or occurrence of a secondary malignancy or death, 
DFS will be censored on the date of the last scan prior to taking the anti-tumor medication.  
Patients who miss 2 or more consecutive tumor scans immediately followed by an event will 
be censored at the date of the last objective tumor assessment prior to the missing/not 
readable scans. 
7.1.2. Secondary Endpoints 
OS is defined as the time from the date of randomization to the date of death due to any 
cause.  In the absence of confirmation of death, survival time will be censored at the last date 
the patient is known to be alive.  Patients lacking data beyond randomization will have their 
survival times censored at randomization.  
7.2. Safety Assessments 
7.2.1. Adverse Events 
Assessment of adverse events will include: type, incidence, severity (graded by the National 
Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], 
Version 4.0), timing, seriousness, and relatedness; and laboratory abnormalities. 
Baseline tumor-related signs and symptoms will be recorded as adverse events during the 
trial if they worsen in severity or increase in frequency. 
7.2.2. Laboratory Safety Assessments 
Hematology and blood chemistry will be drawn at the time points described in the Schedule 
of Activities and analyzed at central laboratories (Refer to Appendix 1).  Investigators may 
have additional blood tests performed for the purpose of planning treatment administration, 
dose modification, or following adverse events and should be repeated as clinically needed.  
PT/INR should be performed to monitor patients receiving concomitant warfarin or other 
anti-coagulants and when clinically indicated. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 42 
Thyroid Function Tests (TSH, free T3 and free T4) should be performed for all patients at 
baseline (Cycle 1Day 1 pre-dose).  Subsequently TSH should be done at Cycle 1 Day 15, 
Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, then every 8 weeks thereafter 
starting from Cycle 7 Day 1. TSH, free T3, free T4 should be performed on the next visit for 
any patient who has an elevated TSH in the previous visit.  Hypothyroidism should be treated 
per standard medical practice to maintain euthyroid state with a normal TSH. 
7.2.3. Other Safety Assessments 
Physical examination: A physical examination including, but not limited to, general 
appearance, head, skin, neck, eyes, ears, nose, mouth, throat, breast, lungs, heart, abdomen, 
back, lymph nodes, extremities, thyroid, musculoskeletal, pulses and nervous system will be 
performed.  The physical examination will include examination of known and suspected sites 
of disease.   
Height and body weight: Height will be recorded at screening visit only.  Body weight will 
also be recorded at the start of each 4 week period. 
Vital Signs: Measurements will be made of temperature, BP and pulse rate.  2 BP readings 
should be taken at least 5 minutes apart in the seated position after the patient has been sitting 
quietly for 5 minutes.  
All patients will be issued a blood pressure monitor and blood pressure measurement diary.  
Patients will be asked to record their blood pressure measurements prior to taking each dose 
of study drug (twice daily) for the first 3 months, and once a week thereafter.  Following 
dose modification of study drug or anti-hypertensive medication, or changes of anti-
hypertensive medication, patients should restart blood pressure measurements prior to taking 
each dose of study drug for the first 3 months and once a week thereafter.  Patients should 
record all blood pressure measurements in their patient diary.  BP readings should be taken in 
the seated position after the patient has been sitting quietly for 5 minutes.  Patients should be 
instructed to inform the investigator immediately if their sBP rises above 150 mm Hg, dBP 
rises above 100 mm Hg, or if they develop symptoms perceived to be related to elevated BP 
(eg, headache, visual disturbance). 
ECOG PS: The ECOG PS scale will be used (Appendix 2).  Evaluation of ECOG PS at 
screening should reflect the patient condition just prior to nephrectomy.   
All safety assessments should be repeated as clinically needed. 
8. Adverse Event Reporting 
8.1. Adverse Events 
All observed or volunteered adverse events regardless of treatment group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
sections.  

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 43 
For all adverse events, the investigator must pursue and obtain information adequate both to 
determine the outcome of the adverse event and to assess whether it meets the criteria for 
classification as a serious adverse event (See Section 8.5) requiring immediate notification to 
sponsor or its designated representative.  For all adverse events, sufficient information should 
be obtained by the investigator to determine the causality of the adverse event.  The 
investigator is required to assess causality.  For adverse events with a causal relationship to 
the investigational product, follow-up by the investigator is required until the event or its 
sequelae resolve or stabilize at a level acceptable to the investigator, and sponsor concurs 
with that assessment. 
8.2. Reporting Period 
Serious adverse events require immediate notification to sponsor or its designated 
representative beginning from the time that the patient provides informed consent, which is 
obtained prior to the patient’s participation in the clinical trial, ie, prior to undergoing any 
trial-related procedure and/or receiving investigational product, through and including 
28 calendar days after the last administration of the investigational product.  Any serious 
adverse event occurring any time after the reporting period must be promptly reported if a 
causal relationship to investigational product is suspected.  
Non-serious adverse events should be recorded from the time the patient has taken at least 
one dose of trial treatment through last patient visit.  
If a patient begins a new anticancer therapy, the adverse event reporting period for 
non-serious adverse events ends at the time the new treatment is started.  Death must be 
reported if it occurs during the serious adverse event reporting period after the last dose of 
investigational product, irrespective of any intervening treatment. 
8.3. Definition of an Adverse Event 
An adverse event is any untoward medical occurrence in a clinical investigation patient 
administered a product or medical device; the event need not necessarily have a causal 
relationship with the treatment or usage.  Examples of adverse events include but are not 
limited to:   
• Abnormal test findings; 
• Clinically significant symptoms and signs; 
• Changes in physical examination findings; 
• Hypersensitivity; 
Additionally, they may include the signs or symptoms resulting from: 
• Drug overdose; 
• Drug withdrawal; 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 44 
• Drug abuse; 
• Drug misuse; 
• Drug interactions; 
• Drug dependency; 
• Exposure In Utero. 
Worsening of signs and symptoms of the malignancy under trial should be reported as 
adverse events in the appropriate section of the CRFs.  Disease progression assessed by 
measurement of malignant lesions on radiographs or other methods should not be reported as 
adverse events.  See description of Serious Adverse Events in Section 8.5 with respect to 
disease progression. 
8.4. Abnormal Test Findings 
The criteria for determining whether an abnormal objective test finding should be reported as 
an adverse event are as follows:  
• Test result is associated with accompanying symptoms; and/or 
• Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or 
• Test result leads to a change in trial dosing or discontinuation from the trial, 
significant additional concomitant drug treatment, or other therapy; and/or 
• Test result is considered to be an adverse event by the investigator or sponsor. 
Merely repeating an abnormal test, in the absence of any of the above conditions, does not 
constitute an adverse event.  Any abnormal test result that is determined to be an error does 
not require reporting as an adverse event. 
8.5. Serious Adverse Events 
A serious adverse event or serious adverse drug reaction is any untoward medical occurrence 
at any dose that: 
• Results in death; 
• Is life-threatening (immediate risk of death); 
• Requires inpatient hospitalization or prolongation of existing hospitalization; 
• Results in persistent or significant disability/incapacity; 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 45 
• Results in congenital anomaly/birth defect. 
Progression of the malignancy under trial (including signs and symptoms of progression) 
should not be reported as a serious adverse event unless the outcome is fatal during the trial 
or within the safety reporting period.  Hospitalization due to signs and symptoms of disease 
progression should not be reported as serious adverse event.  If the malignancy has a fatal 
outcome within the safety reporting period, then the event leading to death must be recorded 
as an adverse event and as a serious adverse event with CTCAE Grade 5 (See Section 8.7, 
Severity Assessment).  Any histopathologically confirmed secondary malignancy must be 
reported as SAE. 
Medical and scientific judgment should be exercised in determining whether an event is an 
important medical event.  An important medical event may not be immediately 
life-threatening and/or result in death or hospitalization.  However, if it is determined that the 
event may jeopardize the patient and/or may require intervention to prevent one of the other 
outcomes listed in the definition above, the important medical event should be reported as 
serious. 
Examples of such events are intensive treatment in an emergency room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency or drug abuse.1  
8.6. Hospitalization 
Adverse events reported from clinical trials associated with hospitalization or prolongation of 
a hospitalization are considered serious.  Any initial admission (even if less than 24 hours) to 
a healthcare facility meets these criteria.  Admission also includes transfer within the hospital 
to an acute/intensive care unit (eg, from the psychiatric wing to a medical floor, medical floor 
to a coronary care unit, neurological floor to a tuberculosis unit). 
Hospitalization does not include the following: 
• Rehabilitation facilities; 
• Hospice facilities; 
• Respite care (eg, caregiver relief); 
• Skilled nursing facilities; 
• Nursing homes; 
• Routine emergency room admissions; 
• Same day surgeries (as outpatient/same day/ambulatory procedures). 
                                                 
1 21CFR 312.32 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 46 
Hospitalization or prolongation of hospitalization in the absence of a precipitating, clinical 
adverse event is not in itself a serious adverse event.  Examples include:  
• Admission for treatment of a preexisting condition not associated with the 
development of a new adverse event or with a worsening of the preexisting condition 
(eg, for work-up of persistent pre-treatment lab abnormality); 
• Social admission (eg, patient has no place to sleep); 
• Administrative admission (eg, for yearly physical exam); 
• Protocol-specified admission during a clinical trial (eg, for a procedure required by 
the trial protocol); 
• Optional admission not associated with a precipitating clinical adverse event (eg, for 
elective cosmetic surgery); 
• Pre-planned treatments or surgical procedures should be noted in the baseline 
documentation for the entire protocol and/or for the individual patient; 
• Admission exclusively for the administration of blood products. 
Diagnostic and therapeutic non-invasive and invasive procedures, such as surgery, should not 
be reported as adverse events.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an adverse event.  For example, an 
acute appendicitis that begins during the adverse event reporting period should be reported as 
the adverse event, and the resulting appendectomy should be recorded as treatment of the 
adverse event. 
8.7. Severity Assessment 
If required on the adverse event CRFs, the investigator will use the following definitions of 
severity in accordance with National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0 to describe the maximum intensity of the adverse 
event.   
GRADE 
Clinical Description of Severity 
0 
No Change from Normal or Reference Range (This grade is not included in the 
Version 4.0 document but may be used in certain circumstances). 
1 
MILD Adverse Event 
2 
MODERATE Adverse Event 
3 
SEVERE Adverse Event 
4 
LIFE-THREATENING OR DISABLING Adverse Event 
5 
DEATH RELATED TO Adverse Event 
 
Note the distinction between the severity and the seriousness of an adverse event.  A severe 
event is not necessarily a serious event.  For example, a headache may be severe (interferes 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 47 
significantly with patient's usual function) but would not be classified as serious unless it met 
one of the criteria for serious adverse events, listed above. 
8.8. Causality Assessment 
The investigator’s assessment of causality must be provided for all adverse events (serious 
and non-serious).  An investigator’s causality assessment is the determination of whether 
there exists a reasonable possibility that the investigational product caused or contributed to 
an adverse event.  If the investigator’s final determination of causality is unknown and the 
investigator does not know whether or not investigational product caused the event, then the 
event will be handled as “related to investigational product” for reporting purposes.  If the 
investigator's causality assessment is “unknown but not related to investigational product,” 
this should be clearly documented on trial records.   
In addition, if the investigator determines a serious adverse event is associated with trial 
procedures, the investigator must record this causal relationship in the source documents and 
CRF, as appropriate, and report such an assessment in accordance with the serious adverse 
event reporting requirements, if applicable. 
8.9. Exposure In Utero 
For investigational products within clinical trials, an Exposure In-Utero (EIU) occurs if: 
1. A female becomes, or is found to be, pregnant either while receiving or having 
been directly exposed to (eg, environmental exposure) the investigational product, 
or the female becomes, or is found to be, pregnant after discontinuing and/or 
being directly exposed to the investigational product (maternal exposure); 
2. A male has been exposed, either due to treatment or environmental, to the 
investigational product prior to or around the time of conception and/or is exposed 
during the partner pregnancy (paternal exposure). 
If any trial patient or trial patient’s partner becomes or is found to be pregnant while 
receiving the investigational product or within 6 months of the last treatment on study, the 
investigator must submit this information to sponsor on a Pregnancy Reporting Form.  In 
addition, the investigator must submit information regarding environmental exposure to the 
investigational product in a pregnant woman (eg a nurse reports that she is pregnant and has 
been exposed to a cytotoxic product by inhalation or spillage) using the Pregnancy Reporting 
Form.  This must be done irrespective of whether an adverse event has occurred and within 
24 hours of awareness of the pregnancy.  The information submitted should include the 
anticipated date of delivery (see below for information related to induced termination of 
pregnancy). 
Follow-up is conducted to obtain pregnancy outcome information on all pregnancy reports 
with an unknown outcome.  The investigator will follow the pregnancy until completion or 
until pregnancy termination (ie, induced abortion) and then notify sponsor of the outcome.  
The investigator will provide this information as a follow up to the initial Pregnancy 
Reporting Form.  The reason(s) for an induced abortion should be specified.  A pregnancy 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 48 
report is not created when an ectopic pregnancy report is received since this pregnancy is not 
usually viable.  Rather, a serious adverse event case is created with the event of ectopic 
pregnancy. 
If the outcome of the pregnancy meets the criteria for immediate classification as a serious 
adverse event (ie, spontaneous abortion, stillbirth, neonatal death, or congenital anomaly 
[including that in an aborted fetus, stillbirth or neonatal death]), the investigator should 
follow the procedures for reporting serious adverse events. 
In the case of a live birth, the “normality” of the newborn can be assessed at the time of birth 
(ie, no minimum follow-up period of a presumably normal infant is required before a 
Pregnancy Reporting Form can be completed).  The “normality” of an aborted fetus can be 
assessed by gross visual inspection, unless pre-abortion test findings are suggestive of a 
congenital anomaly. 
Additional information about pregnancy outcomes that are classified as serious adverse 
events follows:  
• “Spontaneous abortion” includes miscarriage and missed abortion. 
• All neonatal deaths that occur within 1 month of birth should be reported, without 
regard to causality, as serious adverse events.  In addition, any infant death after 
1 month that the investigator assesses as possibly related to the in utero exposure to 
the investigational agent should be reported. 
8.10. Withdrawal Due to Adverse Events (See Also Patient Withdrawal) 
Withdrawal due to adverse event should be distinguished from withdrawal due to insufficient 
response, according to the definition of adverse event noted earlier, and recorded on the 
appropriate adverse event CRF page.   
When a patient withdraws due to a serious adverse event, the serious adverse event must be 
reported in accordance with the reporting requirements defined below. 
8.11. Eliciting Adverse Event Information 
The investigator is to report all directly observed adverse events and all adverse events 
spontaneously reported by the trial patient.  In addition, each trial patient will be questioned 
about adverse events in general. 
8.12. Reporting Requirements 
Each adverse event is to be assessed to determine if it meets the criteria for serious adverse 
event.  If a serious adverse event occurs, expedited reporting will follow local and 
international regulations, as appropriate. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 49 
Adverse events reporting, including suspected serious unexpected adverse reactions, will be 
carried out in accordance with applicable local regulations.  In this clinical trial, the reference 
document for determining whether an event is unexpected is the Investigator’s Brochure. 
All adverse events and serious adverse events will be reported via eCRF.  Adverse events 
should be reported using concise medical terminology in the AE page as well as in the SAE 
page of the eCRF. 
8.12.1. Serious Adverse Event Reporting Requirements 
If a serious adverse event occurs, Sponsor is to be notified via eCRF within 24 hours of 
awareness of the event by the investigator.  In particular, if the serious adverse event is fatal 
or life-threatening, notification to sponsor must be made immediately, irrespective of the 
extent of available adverse event information.  This timeframe also applies to additional new 
information (follow-up) on previously reported serious adverse event reports as well as to the 
initial and follow-up reporting of Exposure in Utero cases. 
In the rare event that the investigator does not become aware of the occurrence of a serious 
adverse event immediately (eg, if an outpatient trial patient initially seeks treatment 
elsewhere), the investigator is to report the event via eCRF within 24 hours after learning of 
it and document the time of his/her first awareness of the adverse event. 
For all serious adverse events, the investigator is obligated to pursue and provide information 
to sponsor in accordance with the timeframes for reporting specified above.  In addition, an 
investigator may be requested by sponsor to obtain specific additional follow-up information 
in an expedited fashion.  This information may be more detailed than that captured in the 
SAE page of eCRF.  In general, this will include a description of the adverse event in 
sufficient detail to allow for a complete medical assessment of the case and independent 
determination of possible causality.  Information on other possible causes of the event, such 
as concomitant medications and illnesses must be provided.  In the case of a patient death, a 
summary of available autopsy findings must be reported as soon as possible to sponsor or its 
designated representative.  
8.12.2. Non-Serious Adverse Event Reporting Requirements 
Non-serious adverse events are to be reported on the adverse event CRFs, which are to be 
submitted to sponsor. 
9. DATA ANALYSIS/STATISTICAL METHODS 
Two analysis populations will be defined: 
1. Intent-to-Treat Population: This population will include all patients who are 
randomized, with study drug assignment designated according to initial 
randomization, regardless of whether patients receive study drug or receive a different 
drug from that to which they were randomized.  This will be the primary population 
for evaluating all efficacy endpoints as well as patient characteristics.  

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 50 
2. As-Treated Population: The as-treated population consists of all patients who 
received at least 1 dose of study drug with treatment assignments designated 
according to actual study drug received.  This population will be the primary 
population for evaluating study drug administration/compliance and safety.  
9.1. Sample Size Determination  
The patient population in this study can be classified into 4 risk groups: 
a. 
pT2, pN0 or pNx, M0 and ECOG 0-1 
b. pT3, pN0 or pNx, M0 and ECOG 0-1 
c. 
pT4, pN0 or pNx, M0 and ECOG 0-1 
d. Any pT, pN1, M0 and ECOG 0-1 
Sample size was determined based on the analysis on the primary endpoint, DFS. 
The sample size for this study was calculated based on the following assumptions: 
• Time to DFS event follows an exponential distribution.  
• The percentage of patients randomized from the 4 risk groups, 2-year DFS rates for 
placebo arm and axitinib arm are assumed below 
Categories 
Risk groups 
Percentage of 
patients 
2-year DFS rate for 
placebo arm 
2-year DFS rate for 
axitinib arm 
1 
a. pT2/pN0 or pNX/M0 
b. pT3/pN0 or pNX/M0 
90% 
70% 
79% 
2 
c. pT4/pN0 or pNX/M0 
1% 
35% 
61% 
3 
d. Any pT/pN1/M0 
9% 
33% 
51% 
 
The assumptions of 2-year DFS rates for the placebo arm and axitinib arm are equivalent to 
the assumptions of hazard ratios to be 0.66, 0.47, and 0.61 for the 3 categories 1, 2 and 3 
respectively.  Given the assumed distribution of patients randomized (1:1) into each of these 
categories, the overall hazard ratio is estimated to be 0.654. 
Based on the above assumptions, a minimal number of 245 DFS events will be required to 
provide 90% power to detect the statistical difference in DFS with HR ≤ 0.654 between the 
two treatment groups with 2-sided significance level of 0.05. 
Applying a 1:1 randomization and a planned accrual period of 24 months, a maximum 
follow-up period of 60 months (5 years), and an assumed 23% drop-out rate by 18 months, it 
was estimated that approximately 700 patients will be enrolled. 
The final analysis will take place when approximately 245 DFS events are observed. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 51 
9.2. Efficacy Analysis 
9.2.1. Analysis of Primary Endpoint  
DFS based on the IRC review of tumor assessments (by imaging or histo-/cytopathology 
reports in the absence of IRC imaging confirmation) is the primary endpoint in this study.  
Factors (and levels in each factor) used in the stratified log-rank test will be stated in the 
SAP. 
The median DFS along with corresponding 95% CI will be estimated for each arm using 
Kaplan-Meier (KM) methods.  The hazard ratio (Arm A/Arm B) will be estimated by 
proportional Hazard regression stratified by the factors used in the stratified log-rank test, 
and with treatment in the model.  The DFS rates at 2 years and 5 years will also be estimated 
for each arm. 
The following sensitivity analyses will be performed for DFS: 
• DFS defined as in the primary analysis but based on local investigator assessment 
rather than IRC assessment.  The earlier of the tumor scan date and the date of 
collection of histo-/cytopathology specimen (where applicable) confirming recurrence 
or secondary malignancy will be used. 
• DFS based on IRC review defined as in the primary analysis but without censoring 
patients who receive further anti-tumor therapy or missed 2 or more consecutive 
tumor scans prior to recurrence or occurrence of a secondary malignancy or death.  In 
other words, patients receiving further anti-tumor therapy or missing 2 or more 
consecutive tumor scans before disease recurrence or occurrence of a secondary 
malignancy or death will be assigned with DFS events at the first date of recurrence 
or occurrence of a secondary malignancy or death.  In the absence of DFS event, DFS 
time will be censored at the date of last scan prior to the time of analyses.  Patients 
alive who do not have post baseline disease assessment will have their DFS times 
censored at randomization. 
• DFS based on IRC review defined as in the primary analysis but considering start of 
new anti-tumor therapy prior to recurrence, occurrence of secondary malignancy or 
death as events at the time of new anti-tumor therapy.   
• DFS based on IRC review as defined for the primary analysis but instead assigning 
the dates for events and censoring at the scheduled scan dates instead of the actual 
scan dates or the date of collection of histo-/cytopathology specimen.  Specifically, 
events that occur within +/- 4 weeks of a scheduled scan will be considered an event 
at the scheduled scan.  Events outside the 4 week window will be counted as events at 
the next scheduled scan time and censoring outside the 4 week window would be 
censored at the previous scheduled scan date. If, however, the event is death, the date 
of death will be used as the event date unless anti-tumor therapy was received prior to 
the date of death in which case the subject will be censored at the scheduled scan date 
prior to the date of anti-tumor therapy or for patients who miss 2 or more consecutive 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 52 
tumor scans immediately followed by an event will be censored at the date of the last 
objective tumor assessment prior to the missing/not readable scans. 
• A parametric model utilizing techniques for interval-censored data will be used to 
compare the treatment effect.   
9.2.2. Analysis of Secondary Endpoints  
OS will be compared between Arm A and Arm B using a stratified log-rank test as described 
in the primary analysis for DFS.  The median OS along with corresponding 95% CI will be 
estimated by treatment arm using KM methods.  The hazard ratio (Arm A/Arm B) will be 
estimated by Proportional Hazard Regression stratified by the factors used in the stratified 
log-rank test and with treatment in the model.  
9.3. Analysis of Other Endpoints 
9.3.1. Patient Disposition 
The number of patients enrolled, treated, and evaluated for safety will be summarized.  In 
addition, the number of patients who completed the study and the number of patients who 
withdrew from the study and reasons for discontinuation will be summarized.  
9.3.2. Baseline Characteristics 
Demographic characteristics such as age, gender, height, weight, race, prior therapy, prior 
medication, physical examination, ECOG PS, signs and symptoms, and medical/oncology 
history will be tabulated. 
9.3.3. Study drug Administration/Compliance 
Study drug administration will be described in terms of the total number and median number 
of doses administered (ie, total dose), and reasons for the deviations from planned therapy. 
9.4. Safety Analysis 
Safety data will be summarized for all patients receiving at least one dose of study drug. 
9.4.1. Analysis of Adverse Events 
The serious adverse event reporting experience for this study begins from the time that the 
patient provides informed consent while the adverse event reporting experience for this study 
begins upon receiving the first dose of study drug and ends 28 days after the last dose of 
study drug is administered.  All AEs (serious and non-serious) reported from the first day of 
study treatment up to 28 days post study treatment will be considered treatment emergent 
AEs (TEAEs).   
Frequencies of patients experiencing at least one AE will be displayed by body system and 
preferred term according to MedDRA terminology.  Detailed information collected for each 
AE will include: A description of the event, duration, whether the AE was serious, intensity, 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 53 
relationship to study drug, action taken, and clinical outcome.  Intensity (severity) of the AEs 
will be graded according to the CTCAE Version 4.0.  Emphasis in the analysis will be placed 
on AEs classified as treatment emergent. 
Summary tables will present the number of patients observed with TEAEs and corresponding 
percentages.  Within each table, the AEs will be categorized by MedDRA body system and 
preferred term.  Additional subcategories will be based on event intensity and relationship to 
study drug. 
Individual patient listings will be prepared for all AE data. 
9.4.2. Analysis of Clinical Laboratory Data 
Listing tables will be prepared for each laboratory measure and will be structured to permit 
review of the data per patient as they progress on treatment.   
Summary tables will be prepared to examine the distribution of laboratory measures over 
time.  Shift tables may be provided to examine the distribution of laboratory toxicities. 
9.4.3. Prior/Concomitant Medications and Non Drug Treatments/Procedures 
Prior medications, defined as those medications stopped prior to the first day of study 
treatment, and concomitant medications, defined as medications stopped, ongoing or started 
on or after the first day of study treatment up to 28 days post the last dose of study treatment, 
will be summarized, using the WHO-drug coding dictionary.  In addition, concomitant non 
drug treatments/procedures will be summarized using the MedDRA coding dictionary. 
9.4.4. Vital Sign and ECOG PS 
Descriptive statistics will be provided for ECOG PS at each assessment time.   
9.5. Interim Analysis  
A single interim analysis (IA) will be performed in the study.  O’Brien – Fleming type 
stopping boundaries based on the Lan-DeMets spending function will be applied.  Futility 
criteria are not used to calculate the nominal alphas (non-binding method) in order to control 
the overall Type I error. 
The interim analysis will take place after the first 184 events (75% of the events as assessed 
by the IRC) have occurred.  If the event occurrence pace is much slower than anticipated, the 
IA could be performed when less than 184 events observed (<75% of the total required) at 
sponsor’s discretion with the Data Monitoring Committee’s (DMC) consensus. 
The objectives of the interim analysis will be: 
1. To assess safety, including any unexpected toxicity.  If the results of the interim 
analysis indicate serious safety concerns, the Sponsor will consult with HRAs 
regarding stopping the clinical trial. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 54 
2. To allow for early stopping of the trial due to futility.  If the conditional power is low, 
the sponsor may choose to stop following up patients.  Conditional power 
calculations will be performed using SAS Version 9.2.  Criteria for futility will be 
provided in SAP. 
3. If the results of the interim analysis demonstrate statistically significant differences 
between the 2 treatment arms for DFS, the sponsor, in consultation with HRAs, will 
disseminate the results of the trial, and the interim analysis may be considered the 
final analysis for DFS.  The nominal level of significance for the interim analysis of 
DFS determined using the Lans-DeMets procedure with an O’Brien-Fleming type 
stopping rule will be 0.0194 (if the interim analysis is performed at 184 events). 
The following table summarizes the nominal significance level (2-sided) at each analysis 
when 75% and 100% of events are observed at the interim analysis and the final analysis. 
 
Fraction of total events 
Nominal α level 
75% 
0.0194 
100% 
0.0442 
 
The actual nominal α levels for the interim analysis and for the final analysis will depend on 
the fraction of total events occurred at the time of interim analysis. 
At the interim analysis statistical hypothesis tests will be performed only for the primary 
efficacy parameter, DFS (based on the IRC tumor assessments).  The stratified log-rank 
statistic will be calculated.  The DFS curve and OS curve estimated by the method of 
Kaplan-Meier will be summarized for each treatment group.  The interim safety report will 
review all aspects of the data collected for each patient.  Other important additional factors 
that reflect the integrity of the protocol will be addressed in the interim report. 
As per sponsor policy with respect to interim analyses of ongoing mortality studies, 
distribution of the analyses will be limited to appropriate individuals within the entire 
organization.  Results will be presented at the treatment group level only.  The results will 
not be shared with all the study team members or investigators nor broken down by center. 
9.6. Data Monitoring Committee  
A Data Monitoring Committee (DMC) will be formed to assure patient safety in this clinical 
trial.  The DMC will include a panel of experts recruited from outside of the institutions 
involved in this study.  The DMC will have access to unblinded patient treatment assignment 
information.  The DMC members will also have additional responsibility as they will be 
involved in the conduct and interpretation of data analyses for efficacy in addition to their 
primary responsibility for patient safety.  The committee will review tabulated aggregate 
toxicity and endpoint data.  The committee will submit written recommendations on the 
progress of the study to the Sponsor.  
Further procedural matters and meeting schedule will be defined by mutual agreement of 
DMC members in accordance with sponsor guidelines.  

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 55 
9.7. Independent Review Committee (IRC) 
The radiographic images and/or available local histo-/cytopathology reports (for patients who 
have site confirmation of recurrence or occurrence of secondary malignancy in the absence 
of IRC imaging confirmation) will be evaluated by an IRC to assess tumor status and to 
confirm recurrence or occurrence of a secondary malignancy.  The radiographic images 
and/or histo-/cytopathology reports documenting efficacy endpoints must be made available 
to allow the independent review.  The core laboratory will work with each clinical site to 
institute an acquisition protocol and other processes that will allow electronic transfer, where 
possible, of appropriate information used for tumor assessments.  Two independent reviewers 
will read scans.  Differences between the two independent reviewers should be resolved by a 
third reviewer (adjudicator) for final determination.  In addition, an independent clinical 
oncologist will assess available local histo-/cytopathology reports for evidence of malignancy 
for patients for which there is site confirmation of recurrence or occurrence of secondary 
malignancy in the absence of IRC imaging confirmation.  For primary statistical analysis, the 
results of the independent review will be used.   
10. QUALITY CONTROL AND QUALITY ASSURANCE 
During trial conduct, Sponsor or its agent will conduct periodic monitoring visits to ensure 
that the protocol and GCPs are being followed.  The monitors will review source documents 
to confirm that the data recorded on CRFs is accurate.  The investigator and institution will 
allow sponsor monitors or its agents and appropriate regulatory authorities direct access to 
source documents to perform this verification. 
The trial site may be subject to review by the Institutional Review Board (IRB)/Independent 
Ethics Committee (IEC), and/or to quality assurance audits performed by sponsor, and/or to 
inspection by appropriate regulatory authorities. 
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.  
11. DATA HANDLING AND RECORD KEEPING 
11.1. Case Report Forms/Electronic Data Record 
A CRF is required and should be completed for each included patient.  The completed 
original CRFs are the sole property of sponsor and should not be made available in any form 
to third parties, except for authorized representatives of sponsor or appropriate regulatory 
authorities, without written permission from sponsor. 
It is the investigator's responsibility to ensure completion and to review and approve all 
CRFs.  CRFs must be signed by the investigator or by an authorized staff member.  These 
signatures serve to attest that the information contained on the CRFs is true.  At all times, the 
investigator has final personal responsibility for the accuracy and authenticity of all clinical 
and laboratory data entered on the CRFs.  Patient source documents are the investigator's 
patient records maintained at the trial site.  In most cases, the source documents will be the 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 56 
hospital's or the investigator's chart.  In cases where the source documents are the hospital or 
the investigator's chart, the information collected on the CRFs must match those charts.  
In some cases, the CRF may also serve as the source document.  In these cases, Sponsor and 
the investigator must prospectively document which items will be recorded in the source 
documents and for which items the CRF will stand as the source document. 
11.2. Record Retention 
To enable evaluations and/or audits from regulatory authorities or sponsor, the investigator 
agrees to keep records, including the identity of all participating patients (sufficient 
information to link records, eg, CRFs and hospital records), all original signed ICD, copies of 
all CRFs, serious adverse event forms, source documents, and detailed records of treatment 
disposition.  The records should be retained by the investigator according to ICH, local 
regulations, or as specified in the Clinical Study Agreement, whichever is longer. 
If the investigator relocates, retires, or for any reason withdraws from the trial, Sponsor 
should be prospectively notified.  The trial records must be transferred to an acceptable 
designee, such as another investigator, another institution, or to sponsor.  The investigator 
must obtain sponsor's written permission before disposing of any records, even if retention 
requirements have been met. 
12. ETHICS 
12.1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
It is the responsibility of the investigator to have prospective approval of the trial protocol, 
protocol amendments, ICD, and other relevant documents, eg, advertisements, if applicable, 
from the IRB/IEC.  All correspondence with the IRB/IEC should be retained in the 
Investigator File.  Copies of IRB/IEC approvals should be forwarded to sponsor. 
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is 
where the change is necessary to eliminate apparent immediate hazards to the patients.  In 
that event, the investigator must notify the IRB/IEC and sponsor in writing within 5 working 
days after the implementation. 
12.2. Ethical Conduct of the Trial 
The trial will be performed in accordance with the protocol, International Conference on 
Harmonization Good Clinical Practice guidelines, and applicable local regulatory 
requirements and laws. 
12.3. Patient Information and Consent 
All parties will ensure protection of patient personal data and will not include patient names 
on any sponsor forms, reports, publications, or in any other disclosures.  In case of data 
transfer, Sponsor will maintain high standards of confidentiality and protection of patient 
personal data. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 57 
The ICD must be agreed to by sponsor and the IRB/IEC and must be in compliance with ICH 
GCP, local regulatory requirements, and legal requirements. 
The investigator must ensure that each trial patient, or his/her legally acceptable 
representative, is fully informed about the nature and objectives of the trial and possible risks 
associated with participation.  The investigator, or a person designated by the investigator, 
will obtain written ICD each patient or the patient's legally acceptable representative before 
any trial-specific activity is performed.  The ICD used in this trial, and any changes made 
during the course of the trial, must be prospectively approved by both the IRB/IEC and 
sponsor before use.  The investigator will retain the original of each patient's signed ICD. 
13. DEFINITION OF END OF TRIAL  
End of Trial in all participating countries is defined as collection of the final data point in the 
study.  Because this clinical trial includes a survival endpoint, the last data point is 
anticipated to be the last survival follow-up (ie, date last known alive or of death) prior to the 
cutoff date for database lock for the final Clinical Study Report.  
If the trial is terminated upon recommendation by the DMC according to prospectively-
defined criteria, End of Trial is defined as the date upon which sponsor received notification 
of the decision of the DMC. 
14. SPONSOR DISCONTINUATION CRITERIA 
Premature termination of this clinical trial may occur because of a regulatory authority 
decision, change in opinion of the IRB/IEC, drug safety problems, DMC, or at the discretion 
of sponsor.  In addition, Sponsor retains the right to discontinue development of axitinib, at 
any time. 
If a trial is prematurely terminated or discontinued, Sponsor will promptly notify the 
participating investigators.  After notification, the investigators must contact all participating 
patients within a week of notification.  As directed by sponsor, all trial materials must be 
collected and all CRFs completed to the greatest extent possible. 
15. PUBLICATION OF TRIAL RESULTS 
Sponsor supports the exercise of academic freedom and has no objection to publication by 
the principal investigator (PI) of the results of the study based on information collected or 
generated by the PI, whether or not the results are favorable to the Sponsor’s, and/or the 
Investigational product owner.  However, to ensure against inadvertent disclosure of 
confidential information or unprotected inventions, the investigator will provide Sponsor’s, 
and/or the Investigational product owner an opportunity to review any proposed publication 
or other type of disclosure of the results of the study (collectively, “publication”) before it is 
submitted or otherwise disclosed. 
The first publication is to be a joint publication covering all investigator sites, and that any 
subsequent publications by the PI will reference that primary publication.  However, if a joint 
manuscript has not been submitted for publication within 18 months of completion or 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 58 
termination of the study at all participating sites, the investigator is free to publish separately, 
subject to the other requirements of this section. 
If there is any conflict between this protocol and the CSA, this protocol will control as to any 
issue regarding treatment of study patients, and the CSA will control as to all other issues. 
16. REFERENCES 
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 
v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 
Lyon, France: International Agency for Research on Cancer; 2010. Available from: 
http://globocan.iarc.fr, accessed on day/month/year. 
2. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical 
resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J 
Clin Oncol 1994; 12:206-12. 
3. Zbar B, Brauch H, Talmadge C, Linehan M.  Loss of alleles of loci on the short arm of 
chromosome 3 in renal cell carcinoma. Nature 1987; 327:721-7. 
4. Gnarra JR, Troy K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL 
tumor suppressor gene in renal carcinoma. Nature Genet 1994; 7:85-90. 
5. Brown LF, Berse B, Tognazzi K, Manseau EJ, Van de Water L, Senger DR, et al. 
Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 
1992; 42:1457-61. 
6. Takahashi A, Sasaki AH, Kim SJ, et al. Markedly increased amounts of messenger RNAs 
for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma 
associated with angiogenesis. Cancer Res 1994; 54:4233-7. 
7. Shraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, et al. VHL mutations and 
their correlations with tumor cell proliferation, microvessel density and patient prognosis 
in clear cell renal cell carcinoma. J Pathol 2002; 196:186-93. 
8. Nicol D, Hii SI, Walsh M, The B, Thompson L, Kennett C, et al. Vascular endothelial 
growth factor expression is increased in renal cell carcinoma. J Urol 1997; 157:1482 6. 
9. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al: Improved 
prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 
2001; 19:1649-1657. 
10. Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective 
randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients 
with advanced renal cell cancer. J Clin Oncol 1999; 17:2859-67.  
11. Fosså SD. Interferon in metastatic renal cell carcinoma. Seminars in Oncology 2000; 
27:187-93. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 59 
12. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et 
al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer 
using high-dose bolus interleukin-2. JAMA 1994; 271:907-13. 
13. Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP,. Phase 
II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a 
Southwest Oncology Group study. J Natl Cancer Inst 1990; 82:143-6. 
14. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of 
treatment of 255 patients with metastatic renal cell carcinoma who received high-dose 
recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-96. 
15. Gitlitz BJ, Hoffman DM, Moldawer N, Belldegrun A, Figlin RA. Treatment of metastatic 
renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an 
analysis of 124 consecutively treated patients. Cancer J 2001; 7:112-21. 
16. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, 
et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for 
the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994; 
12:1572-6. 
17. Mesing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford EM, et al. Phase 
III study of interferon alpha-NL as adjuvant treatment for respectable renal cell 
carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 
21: 1214-22. 
18. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. 
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients 
with renal cell carcinoma after radical nephrectomy: phase III randomized controlled 
trial. The Lancet 2004; 363:594-599. 
19. Atzpodien J, Schmitt E, Gertenbach U,  Fornara P, Heynemann H, Maskow A, et al. 
Adjuvant treatment with interleukin-2 and inferno alpha2a-based chemoimmunotherapy 
in renal cell carcinoma post tumour nephrectomy: results of a prospectively-randomised 
trial of the German Cooperative Renal Cell Carcinoma Chemoimmunotherapy Group 
(DGCIN). Brit J Cancer 2005; 92:843-846. 
20. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. 
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.  NEJM 2007: 356 (2); 
115-124. 
21. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial 
of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma 
(AVOREN): Final analysis of overall survival. J Clin Oncol 2010; 28(13):2144-50. 
22. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. 
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a 
randomised, double\blind phase III trial. Lancet 2007; 370: 2103-11. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 60 
23. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in 
advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125–134. 
24. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, et al. Axitinib 
treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II 
study. Lancet 2007; 8:975-84. 
25. Motzer RJ, Rouge TM, Harzstark AL, Michaelson MD, Liu G, Gruenwald V, et al. 
Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) 
overall survival (OS) data from a phase II trial. 2011 ASCO Annual Meeting, Poster 
Discussion Session. 
26. Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, et al. Key 
predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II 
study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.  Eur 
J Cancer 2011. 
27. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, et al. Phase II study of 
axitinib in sorafenib-refractory metastatic renal cell carcinoma, J Clin Oncol 2009; 
27(27): 4562-68. 
28. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative 
effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): 
randomized phase 3 trial.  The Lancet 2011; 378: 1931-9. 
29. Kidney. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 
7th ed. New York, NY: Springer, 2010, pp 479-89. 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 61 
APPENDICES 
Appendix 1. Required Laboratory Tests 
Appendix 2. ECOG Performance Status 
Appendix 3. National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) 
Appendix 4. Nephrectomy Procedure  
Appendix 5. Abbreviations and Definitions of Terms 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 62 
Appendix 1. Required Laboratory Tests 
 
Conventional 
Units 
Conversion 
Factor 
SI Units 
Hematology 
Hemoglobin (Hgb) 
g/dL 
x 10 
g/L 
Platelet count (Plt) 
103/mm3 
x 109 
10x12/L 
White blood count (WBC) 
103/mm3 
x 106 
109/L 
White blood cell differential 
Neutrophil 
% 
x 0.01 
fraction 
Lymphocytes 
% 
x 0.01 
fraction 
Chemistry 
Total bilirubin 
mg/dL 
x 17.1 
μmol/L 
Alanine transaminase (ALT) 
U/L 
N/A 
U/L 
Aspartate transaminase (AST) 
U/L 
N/A 
U/L 
Alkaline phosphatase 
U/L 
N/A 
U/L 
Lactic dehydrogenase (LDH) 
U/L 
x 0.016667 
μkat/L 
Albumin 
g/dL 
x 10 
g/L 
Total protein 
g/dL 
x 10 
g/L 
Sodium 
MEq/L 
x 1.0 
mmol/L 
Potassium 
MEq/L 
x 1.0 
mmol/L 
Chloride 
MEq/L 
x 1.0 
mmol/L 
Calcium 
mg/dL 
0.25 
mmol/L  
Phosphate 
mg/dL 
x 0.323 
mmol/L 
Blood urea nitrogen (BUN)/Urea 
mg/dL 
x 0.357 
mmol/L 
Creatinine 
mg/dL 
x 88.4 
μmol/L 
Glucose 
mg/dL 
x 0.055 
mmol/L 
PT/INR 
N/A 
N/A 
N/A 
Thyroid Function Tests 
 
 
 
Thyroid stimulating hormone (TSH) 
µU/mL 
x 1.0 
mIU/L 
Free T3 
pg/dL 
 
 
Free T4 
ng/dL 
 
 
Urinalysis 
 
 
 
Urine Protein 
N/A 
 
 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 63 
Appendix 2. ECOG Performance Status 
Grade 
ECOG 
0 
Fully active, able to carry on all pre-disease activities without restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, eg, light house work or office work 
2 
Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
3 
Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours 
4 
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed 
or chair 
5 
Dead 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 64 
Appendix 3. National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) 
The NCI CTCAE (Version 4.0) has been placed in the Study Reference Binder for this 
protocol.  Alternatively, the NCI CTCAE may be reviewed on-line at the following NCI 
website: 
http://ctep.cancer.gov/reporting/ctc.html 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 65 
Appendix 4. Nephrectomy Procedure 
Radical nephrectomy procedure performed either by open or by laparoscopic technique 
should include: early ligature of the renal vessels and en bloc removal of the intact specimen 
including tumoral kidney and surrounding perinephritic fat.  
Partial nephrectomy can be allowed provided all inclusion criteria are met and surgical 
margins are obtained.  
Adrenal gland removal should be performed in case of large upper pole tumor or in case of 
abnormal adrenal imaging on preoperative CT.  In other cases, routine adrenal gland excision 
is not mandatory and should be performed according to surgeon preferences.  
Lymph node dissection (LND) should be performed in case of suspicion of nodal invasion 
either on preoperative CT imaging or at intra-operative finding.  In other cases, LND will be 
performed according to surgeon preferences.  
In all cases, there must be no evidence of residual macroscopic disease on post-operative CT. 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 66 
Appendix 5.  Abbreviations and Definitions of Terms 
AE  
 
 
Adverse Event 
AIDS   
 
Acquired Immune Deficiency Syndrome 
AJCC  
 
American Joint Committee on Cancer 
ALT  
 
 
Alanine Transaminase 
AST  
 
 
Aspartate Transaminase 
ANC   
 
Absolute Neutrophil Count 
BP 
 
 
Blood Pressure 
BUN   
 
Blood Urea Nitrogen 
CI 
 
 
Confidence Interval 
CRF 
 
 
Case Report Form 
CSF 
 
 
Cerebral Spinal Fluid 
CT 
 
 
Computerized Tomography 
CTCAE  
 
Common Terminology Criteria for Adverse Events (US-NCI) 
CYP3A4/5 
 
Cytochrome P450 enzyme-3A4/5 
dBP 
 
 
diastolic Blood Pressure 
DFS 
 
 
Disease Free Survival 
DMC   
 
Data Monitoring Commitee 
ECG   
 
Electrocardiogram 
ECOG   
 
Eastern Collaborative Oncology Group 
EIU 
 
 
Exposure in Utero 
EQ-5D  
 
European Quality of Life Questionnaire in 5 functional domains 
GCP  
 
 
Good Clinical Practice 
Hgb 
 
 
Hemoglobin 
HIV  
 
 
Human Immunodeficiency Virus 
HRA 
 
 
Health Regulatory Authority 
ICD 
 
 
Informed Consent Document 
ICH 
 
 
International Conference Harmonisation  
IEC  
 
 
Independent Ethics Committee 
IFN-α  
 
Interferon-alfa 
IL-2  
 
 
Interleukin-2 
INR  
 
 
International Normalized Ratio 
IRB  
 
 
Institutional Review Board 
IRC 
 
 
Independent Review Commitee 
IUD 
 
 
Intrauterine Device 
KM 
 
 
Kaplan Meyer 
LDH   
 
Lactic Dehydrogenase 
LND 
 
 
Lymph Node Dissection 
MedDRA  
 
Medical Dictionary for Regulatory Activities 
mRCC  
 
Metastatic Renal Carcinoma  
MRI  
 
 
Magnetic Resonance Imaging 
NCI  
 
 
National Cancer Institute 
ORR 
 
 
Objective response rate 
OS  
 
 
Overall Survival 
PFS 
 
 
Progression Free Survival 
PLT 
 
 
Platelet  
PRO 
  
 
Patient Reported Outcomes 
PT  
 
 
Prothrombin Time 
QTc 
 
 
Corrected Q-T interval 
RCC   
 
Renal Cell Carcinoma 

AP311736 
Version - #10 Mar. 21, 2017 
 
CONFIDENTIAL 
Page 67 
sBP 
 
 
systolic Brood Pressure 
TEAE  
 
Treatment Emergent Adverse Event 
TNM  
 
Tumor, Nodes, Metastases 
TX 
 
 
Treatment 
TSH 
 
 
Thyroid Stimulating Hormone 
ULN   
 
Upper Limit of Normal 
UPC 
 
 
urine protein: urine creatinine ratio 
VEGF   
 
Vascular Endothelial Growth Factor 
WBC   
 
White Blood Cell 
 

Title: Protocol Approval Template 
Document No.: TMP-302-1  
Version No.: 1.0 
 
 
SFJ Pharmaceuticals, Inc.® 
Proprietary and Confidential 
Page 1 of 1 
 
 
 
 
 
 
PROTOCOL APPROVAL SIGNATURE PAGE 
Compound: 
AG-013736 
Compound Name: 
Axitinib 
Protocol Number: 
AP311736 
Phase: 
III 
Version and Date 
version - 10    March 21, 2017 
 
 
 
 
 
Rolf Linke 
Chief Medical Officer 
SFJ Pharmaceuticals 
 
 
                                                                               
 
 
 
               
________________________________________________________________________ 
Rolf Linke 
 
 
 
 
 
 
Date   
 
 
 
21. March 2017